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ABSTRACT 
Insight into the functional and physiological state of a drug target is of essential importance in the drug 
discovery process, with the lack of emerging (3D) drug targets we propose the integration of homology 
modeling which may aid in the accurate yet efficient construction of 3D protein structures. In this study 
we present the applications of homology modeling in drug discovery, a conclusive route map and 
detailed technical guideline that can be utilised to obtain the most accurate model. Even with the 
presence of available drug targets and substantial advancements being made in the field of drug 
discovery, the prevalence of incurable diseases still remains at an all-time high. In this study we explore 
the biological activity of chemically derived fragments from natural products utilising a range of 
computational approaches and implement its use in a new route towards innovative drug discovery. A 
potential avenue referred to as the reduce to maximum concept recently proposed by organic chemists, 
entails reducing the size of a chemical compound to obtain a structural analogs with retained or 
enhanced biological activity, better synthetic approachability and reduced toxicity. Displaying that size 
may not in fact matter.  
Molecular dynamic simulations along with toxicity profiling were comparatively performed, on natural 
compound Anguinomycin D and its derived analog SB 640 each in complex with the CRM1 protein 
which plays an avid role in cancer pathogenesis. Each system was post-dynamically studied to 
comprehend structural dynamics adopted by the parent compound to that exhibited by the analog. 
Although being reduced by 60% the analog SB 640 displayed an overall exhibition of attractive 
pharmacophore properties which include minimal reduction in binding affinity, enhanced synthetic 
approachability and reduced toxicity in comparison to the parent compound. Potent inhibitor of CRM1, 
Leptomycin B (LMB) displayed substantial inhibition of the CRM1 export protein by binding to four 
of the PKIαNES residues (ϕ0, ϕ1, ϕ2, ϕ3, and ϕ4) present within the hydrophobic binding groove of 
CRM1. Although being drastically reduced in size and lacking the presence of the polyketide chain 
present in the parent compound Anguinomycin D and LMB the analog SB 640 displaced three of these 
essential NES residues. The potential therapeutic activity of the structural analog remains undeniable, 
however the application of this approach in drug design still remains ambiguous as to which chemical 
fragments must be retained or truncated to ensure retention or enhanced pharmacophore properties. In 
this study we aimed to implement the use of thermodynamic calculations, which was accomplished by 
incorporating a MM/GBSA per-residue energy contribution footprint from molecular dynamics 
simulation. The proposed approach was generated for each system. Anguinomycin D and analog SB 
640 each in complex with CRM1 protein, each system formed interactions with the conserved active 
site residues Leu 536, Thr 575, Val 576 and Lys 579. These residues were highlighted as the most 
energetically favourable amino acid residues contributing substantially to the total binding free energy. 
Thus implying a conserved selectivity and binding mode adopted by both compounds despite the 
omission of the prominent polyketide chain in the analog SB 640, present in the parent compound. A 
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strategic computational approach presented in this study could serve as a beneficial tool to enhance 
novel drug discovery. This entire work provides an invaluable contribution to the understanding of the 
phenomena underlying the reduction in the size of a chemical compound to obtain the most beneficial 
pharmacokinetic properties and could largely contribute to the design of potent analog inhibitors for a 
range of drug targets implicated in the orchestration of diseases. 
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CHAPTER 1 
1.1 Background and Rationale behind this study  
With high mortality rates, increased drug resistance, lack of effectivity of therapeutic drugs, reduced 
bioavailability and limited availability of resources, a more rational approach to drug design and 
development is required. The identification of prospective bioactive molecules that limit the 
development of a disease condition, remains a crucial component in understanding the molecular 
mechanism of pathogenesis displayed by a drug target. Based on a molecular perspective, these 
requirements translate into a scenario where a drug molecule interacts  with one or more target proteins 
that are directly implicated in the pathophysiology of a disease and may act as inhibitors, agonists or 
modulators1. A full characterization of these interactions on a molecular and structural level may add 
considerable knowledge that can be utilised in drug design processes2. Employing the insight extracted 
directly from the 3D structural details of a drug target may constitute an accurate account of the drug-
protein interaction, providing an acute perspective on the mode of action (MOA) of the drug molecule 
which may further advance the process of drug design3. Utilization of  accurate 3D protein structures 
may ensure drug-target specificity and effectivity4, which is an eminent requirement in all fields of drug 
design.  Therefore not only the identification of potential drug candidates but the availability of accurate 
drug protein targets remains a high priority in structure-based drug design protocols. The availability of 
drug targets, may ensure the development of current therapeutic with enhanced drug target specificity 
and effectivity, potentially reducing developed drug resistance, lack of effectivity and potency. There 
are many fields that take these requirements into consideration in the process of drug design and 
development, however computational chemistry is highlighted as one of the most prominent fields that 
exploits the use of various tools that may aid in the discovery of not only accurate drug targets but 
enables the identification of optimal drug candidates5.  Homology modeling is identified as a potential 
computational approach, utilised to construct a protein 3D structure, by employing the use of a protein 
sequence of a known 3D model as a template. The template sequence of one or more homologous 
proteins with a known structure, is often targeted to construct the most accurate model of the target 
protein6. This study provides a route map that can be used for the construction of the most accurate 3D 
protein structure, accompanied by detailed technical guidelines and the formidable applications of 
homology modeling in drug design over the last decade.  Once the most accurate model of a protein 
target, has been established it then becomes possible to identify potential drug candidates that may 
elucidate avid inhibitory activity against the target protein7.  
In the midst of substantial investments being made in drug discovery, there is a limited  number of new 
chemical entities being introduced to the drug discovery market2,8. The optimization of current 
therapeutic drugs forms an attractive alternative towards bridging the gap in drug design and 
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development9.A relatively new approach introduced by organic chemists known as the “reduce to 
maximum concept”10 entails reducing the size of a chemical compound, by the removal of unwanted 
fragments resulting in retention or improvement of biological parameters such as potency and 
selectivity10. The concept of reducing the size of compound whilst maintaining maximum bioactivity 
presents itself as an ideal platform for next generation drug discovery and design11. From experimental 
studies, the  application of this concept is associated with enhanced synthetic approachability, gain of 
time and resources, reduced toxicity, improved bioavailability and sustained selectivity12.Over the last 
10 decades, natural products have made a resurgence in the field of drug discovery as they harvest 
beneficial pharmacokinetic properties evidently observed  as  nature’s secrets are enshrined in natural 
products13,14. Natural products (NP) are considered to be the ideal target candidates in the application 
of the reduce to maximum concept as they possess chemical fragments that exhibit a vast range of 
beneficial therapeutic properties15. The prime use of statins derived from the natural product lovastatin 
has led to the development of treatment against cardiovascular diseases, which further exemplifies the 
essential role that NPs have played in drug discovery. Organic chemists were able to harvest the pivotal 
chemical scaffold of 3,5-dihydroxypentoate derived from lovastatin, which led to the introduction of 
more potent and therapeutic effective derivatives, with an influential impact on the current state of 
society and medicine today16,17. 
Substantial contributions have been made by synthetic protocols towards the discovery of new 
innovative drugs predominantly in chemical synthesis, however even efforts made by chemical 
synthesis cannot be the sole solution to the  pending disease crisis that looms thus efforts from other 
fields of drug discovery is encouraged18. Computational chemistry is highlighted as the one of the most 
propagated avenues currently integrated in the drug design and discovery process. As the continuous 
implementation of computational methods over the many years in drug discovery has led to a substantial 
reduction in time and resource requirements, which are crucial in chemical synthesis and biological 
protocols19. The use of computational approaches may ultimately alleviate the need for pre-clinical and 
clinical studies and its associated costs. Harvesting the essential knowledge extracted from NPs in 
combination with the technical versatility of computational methods may enable the integration of 
natural products derivatives as displayed in antibody–drug conjugates, stereo-chemical complex 
fragments, or initiate scaffold repurposing, in next generation drug discovery20.  
 
It is proposed the incorporation of the reduce to maximum concept may enable the synthesis of potential 
therapeutic drugs with enhanced potency, and a substantial reduction in the total number of synthetic 
steps21. However, it still remains ambiguous as to which fragments of the chemical compounds are 
essential for activity and which fragments must be truncated. Thus quantitative protocols are required 
to gain insight into the analogy of which fragments of the chemical compound are essential for activity 
and which fragments can be omitted22.In recent years, the use of computational approaches projected 
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in modern drug discovery processes has transpired into a close equivalent to experimental studies, the 
insight extracted from computational tools has provided a better understanding in complex biological 
phenomena23. The use of computational approaches may enable a deeper understanding of the chemical 
compounds structural features and interactions within the active site24, which is imperative as it may 
lead to the generation of molecules that emulate the transition state25,26. Molecular modeling is a robust 
computational tool used to study the conformational dynamics of biological systems. In this work, 
molecular dynamic simulations and in-depth post dynamics analysis were performed for the natural 
parent compound Anguinomycin D and its derived analog SB 640 in complex with CRM1.Chromosome 
Region Maintenance protein 1 (CRM1) plays an essential role in all eukaryote organisms as it mediates 
the transport of cargoes that contain the nuclear export signal (NES) from the nucleus to the cytoplasm27. 
However, the upregulation of this transportation process is primarily associated with common hallmarks 
for a vast spectrum of cancers. The elevation of the CRM1 protein is associated with a range of cancers 
such as pancreatic28, kidney29 and ovarian30 along with osteosarcoma31. Current nuclear export 
inhibitors of the CRM1 are associated with elevated levels of toxicity, as displayed by bacterial inhibitor 
Leptomycin B32. Anguinomycin D shares close structural features to Leptomycin B, thus displays 
inhibitory activity against the CRM1 protein. From experimental studies, it was observed structural 
analog of Anguinomycin D, analog SB 640 which is reduced by 60% in its structure maintained the 
inhibitory activity and overall  retention of bioactivity33 displayed by the parent compound 
Anguinomycin D.  
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.1 Displays the structure of natural products Leptomycin B, which shares close structural 
similarity to Anguinomycin D and its derived analog SB 640 
 
  
Leptomycin B 
Analog SB 640 Anguinomycin B 
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This study aimed to validate the “reduce to maximum concept” and provide further insight in the 
application of a range of computational approaches that may aid in the implementation of this concept 
in the design of potential drugs. Per-residue energy decomposition analysis has become an effective 
approach to drug discovery. Its use in drug design enables the identification of the most highly 
contributing amino acid residues to the total binding affinity25, which can be correlated to determine 
which fragments of the chemical compound are imperative for the molecular and physiochemical 
properties exhibited by a compound. Per-residue energy decomposition footprints were performed in 
this study to provide a guideline in distinguishing which fragments of a chemical compound must be 
retained from the large parent structural and chemical composition to elucidate biological activity and 
which fragments of a chemical compound can be omitted as its presence may assert toxicity, resulting 
in desired pharmacophore properties exhibited by the truncated analog.  
 
1.2. Novelty and significance of this study 
With the lack of accurate 3D protein models currently available the ability to establish the molecular 
mechanism of drug interaction between a potential drug candidate and protein target involved in the 
infestation of a disease condition still remains ambiguous, this study elucidates the use of computational 
tool of homology modeling which provides a conclusive route map that can be utilized to generate the 
most accurate 3D protein model. Once the identification of a target protein is established the next step 
in effective drug design is to generate effective yet potent drug targets.  NPs remain as the sole source 
and the best inspiration for the drug-discovery process. This study aims to reveals the impact of the 
integration of experimental and theoretical approaches as a new form of rational drug discovery. Thus 
we implement the use of computational approaches to gain insight into a relatively new approach 
introduced by organic chemists referred to as the “reduce to maximum concept”, which may lead to 
next generation drug discovery.  
The “reduce to maximum concept” entails the extraction of the most essential fragments of a chemical 
compound derived from natural products to obtain a smaller structural compound with retained or 
enhanced bioactivity, better synthetic approachability and potential reduced toxicity. This approach 
presents itself as an ideal platform for innovative drug discovery10. This study forms as a rationale to 
understand the mechanism of binding, elucidated by the structural analog SB 640 (of Anguinomycin 
D) although being drastically reduced in its size, and in doing so may validate the reduce to maximum 
concept that can be implemented in all fields of drug discovery by implementing screening protocols 
stemming from the use of computational approaches such as binding interaction calculations. Even after 
conclusive experimental studies conducted the level of interaction portrayed by the reduced chemical 
compound, elucidating which structural features are essential for retention or enhanced biological 
activity and which fragments may be omitted remains ambiguous. Utilizing the knowledge extracted 
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from this study may provide a deeper understanding underlying the molecular and structural interaction 
of the reduced analog and the target protein. The inception of this approach, integrated with the 
application of computational tools may form a formidable impact in current drug development, 
cascading the introduction to next generation drug discovery. This study aimed at utilizing 
computational approaches to provide a guideline to decipher which chemical fragments of a compound 
are essential for activity and which fragments can be omitted based on thermodynamic calculations. 
Elucidating that the size of chemical compound may in fact not matter.  
Medicinal chemists and other pharmaceutics have resorted to molecular modelling drug design 
techniques as its application provides insight underlying the mechanism, dynamics  as well as the 
energetics of proteins and protein-drug complexes34,35. Molecular dynamics (MD) is a common tactic 
presently employed to overcome drug resistance and ultimately adopt a protocol that can be 
administered in all fields of drug design. There is no previous theoretical study that unveiled the precise 
molecular level understanding underlying the reduction in the size of a chemical compound and its 
mechanism of inhibitory activity correlating to its reduced size. Computational chemistry integrates 
itself as the most suitable avenue to gain insight into the structural dynamics. This is a first attempt at 
implementing the use of computational approaches such as molecular modeling and per-residue energy 
decomposition analysis to gain insight into the reduction in the size of a compound to further obtain the 
most optimal and desired biological parameters. In this study the computational approach was employed 
to confirm and validate the experimental outcomes and to understand the changes in drug binding 
landscape. We believe this study may provide immeasurable insight into a new approach that can be 
implemented in drug design and development.  
1.3. Aim and Objectives   
This study has three major aims: 
1. To investigate the use of the computational approach of homology modeling, highlighting its active 
role in the drug discovery process: 
To achieve this, the following objectives were outlined: 
 
1.1 The protocol of homology modeling is determined, along with technical guidelines that may result 
in the most accurate  models being generated  
1.2 The application of homology modeling in drug design and discovery was investigated over the last 
decade.  
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2. Validation of  the “reduce to maximum” concept  based on the magnitude of ligand binding affinity 
of the parent compound Anguinomycin D in comparison to the analog SB 640  as well as per-
residue energy decomposition analysis  
 To achieve this, the following objectives were outlined: 
 
2.1 Molecular dynamic simulations were performed along with post MD analysis of the parent 
compound Anguinomycin D and analog SB 640, to analyse the mechanism of binding exhibited by 
both compounds 
2.2 To estimate the ligand binding free energies of Anguinomycin D and its derived analog SB 640 in 
complex with the CRM1 protein to determine if the reduction in the size of chemical compound 
alters the total binding free energy contribution.  
2.3 Per-residue energy decomposition analysis were performed to determine which fragments of the      
chemical compound is essential for the biological activity exhibited and which features of the 
chemical  compound can be omitted. 
3. To determine the toxicity profile of the parent compound Anguinomycin D and the analog SB 64 
To achieve this, the following objectives were outlined: 
 
3.1 The PASS online prediction test were performed for Anguinomycin D and analog SB 640  
  
1.4. Overview of this work 
The format of this thesis is by publication with Chapter4-5 containing copies of papers that have been 
accepted and/or submitted to journals. This thesis is divided into six chapters, with this one included: 
 
Chapter 2: This chapter begins with highlighting the formidable application of homology modeling, in 
the construction of accurate 3D protein targets that can be used in effective drug design. It further 
highlights the “reduce to maximum concept” and its potential application in the drug discovery process. 
It inaugurates the use natural products as a major source for novel compounds, focusing on chemical 
fragments that can be isolated from natural products. It highlights factors associated with the prevalence 
of many diseases, highlighting cancer as one of the highest contributors to the high mortality observed. 
It further focuses on the CRM1 protein which is associated with the pathogenesis of a range of cancers, 
highlighting the first known inhibitor of CRM1, Leptomycin B and its discontinuous use in clinical 
trials, attributed to its associated high levels of toxicity associated with its use, it also highlights the 
inhibitory activity of natural product Anguinomycin D and its drastically reduced structural analog SB 
640 against the CRM1 protein.  
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Chapter 3: This is a brief introduction to computational chemistry, various molecular modeling and 
molecular simulation protocols and their applications. Some computational methods have been 
theoretically explained, followed by a range of computational tools applied in the study of 
Anguinomycin D and its derived analog SB 640 in complex with the CRM1 protein, with the 
fundamental focus on molecular dynamics simulations, binding free energy calculations and homology 
modelling.  
 
Chapter 4 (Manuscript Accepted) 
This chapter presents a review on homology modeling titled “Homology modeling in drug discovery: 
An update on the last decade. It highlights the use of homology modeling in the drug discovery process, 
a technical guideline to construct the more accurate model as well as the application of homology in 
drug discovery over the last decade. 
 
Chapter 5 (Submitted for publication) 
This chapter presents results from the study titled “Size does not matter: A molecular insight into the 
biological activity of chemical fragments using thermodynamic calculations”. It presents data extracted 
from molecular dynamics simulations performed on Anguinomycin D and analog SB 640, as well 
thermodynamic calculations, which elucidated a minimal reduction in the binding free energy of the 
analog in comparison to the Anguinomycin D, enhanced synthetic approachability and an overall 
reduction in toxicity.  
 
Chapter 6  
This chapter expounds the overall concluding remarks of the entire thesis and future plans and 
recommendations
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CHAPTER 2 
2.0 Literature Review  
2.1. Introduction  
The prevalence of incurable diseases has exponentially increased over many years, in spite of the 
substantial investments in the field of drug design and discovery1. The identification of innovative drugs 
emerging from chemical and pharmaceutical industries remains minimal, with accompanying attrition 
rates experiencing an all-time low2.  In order to fully characterise the effectivity of a drug, the mode or 
mechanism of action must be established thus drug target selection prevails as a decisive factor in drug 
discovery research and  productivity3. Since the early inception of the genomics era in the 1990s, the 
sole focus of drug discovery has been focused on the identification of potential drug targets4, ideally 
proteins that play a crucial in disease pathogenesis. Modification of biological activity of the target 
protein form the rational basis for the discovery of new drug candidates5.  A target-centric approach 
imparts a specific biological hypothesis, based on the structural, and molecular composition of the target 
protein, which can be utilised as a starting point for the identification of potential therapeutics6.  
  
In order to gain precise insight into the target protein mechanism and structural dynamics of the model 
of the 3D target protein must be established. Homology modeling is identified as an attractive approach 
branching from the field of computational chemistry. Homology modeling also known as comparative 
modeling can be utilised for the construction of an accurate 3D target model, in a relatively short period 
of time based on the 3D model from a template protein sequence with a known structure7. Homology 
modeling enables the refinement of novel therapeutic drug targets which may aid significantly in drug 
design and development. Once the target protein is available, the definitive mechanism by which a 
potential drug candidate elucidates its inhibitory activity can be proposed, on the basis of its interaction 
with the drug target and its conformational fit within the active site8.  
 
An accurate model of the 3D drug target may enable a better understanding of the role it undertakes 
during the molecular and structural transition leading to the disease state9. Utilizing the crucial 
knowledge extracted from the three-dimensional structure of the biological target, may assist in 
proficient yet cost-efficient lead discovery and optimization5. However the lack of new chemical entities 
towards effective drug discovery depicts how difficult it is to randomly generate potent and selective 
compounds2.The chemical versatility and pharmacophore properties displayed by NPs has been a key 
factor in the resurgence of their use in drug research and development.   
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2.2. Biological activity of Natural products in lead drug discovery  
Natural products (NP) encompass many centuries of un-relinquished potential, the chemical diversity 
confined within NP10,2, continue to illustrate its importance in modern drug discovery efforts. There has 
been an evident resurgence of NPs over the last decade, harvesting the knowledge encompassed in these 
rich commodities results in elevated biological activity, high specificity and reduced toxicity.  
chemically derived fragments with high specificity and beneficial biological activity11.The unique yet 
divergent structural composition of NPs, have certainly broadened the current database of existing 
organic molecules. As the integration of NPs in drug discovery has led to the introduction of novel 
chemical fragments12, with contrasting molecular skeletons and distinctive biological and functional 
features that would otherwise be overlooked, with the application of synthetic protocols13. 
 
2.3. Resurgence of natural products in drug discovery  
In recent times, there has been a relapse in the search towards alternative drug discovery methods, 
limiting the discovery of prospective drug candidates14, required by essential therapeutic areas such as 
immunosuppression15, anti-cancer drugs16, anti-inflammatory and treatment against viral diseases17. 
The therapeutic potential disclosed by NPs reaffirms their promising use in the field of drug design and 
development18. These fields include genetics and enzymology which have gained immeasurable insight 
and thrived, by assimilating the process of biosynthesis of NPs19. NPs have also substantially improved 
industrial sectors such as the pharmaceutical and agriculture industries with the provision of 
considerable insight into the identification of  useful molecules and lead compounds1.  
The contribution of NPs towards the drug discovery substantially supersedes the contributions made by 
combinatorial chemistry which prompts the development of synthesized compounds20. Observations 
have shown that between the years 1981-2010, there has been a minimal contribution of 36% of newly 
discovered chemical entities, that have been synthetically derived with no influence from the structural 
and chemical composition of NPs21. Although there has been a long standing dependence on 
combinatorial chemistry by drug developing companies, minimal progress in drug development has 
been achieved over the many years22,23.  
The intrinsic chemical and structural composition of NPs display a large-scale of diversity in 
comparison to synthetic compounds, consisting of an array of biologically active compounds playing 
an active role of a protagonist in innovative drug discovery24. The use of NPs is illuminated in cancer 
research as they display interesting lead structures with promising chemical entities25. The  versatile 
chemical composition of NPs, make up the fundamental  scaffolds and are considered privileged 
structures, that have been a product of evolution26. The utilization of the chemical fragments harboured 
by NPs has had an immense influence on all spheres of science and has advertently inaugurated the use  
of these chemically derived fragments in the recent process of drug design and discovery27.  
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2.4. Pitfalls in the use of natural products as potential drug leads 
There are various liable reasons for the scepticism associated with the current integration of NPs in drug 
discovery, as the time and protocol required for NPs isolation is a rather consuming and an elaborate 
affair. The ability to differentiate existing chemical compounds from NP, from those that may be newly 
discovered to avoid strenuous synthetic protocols associated with de-replication still remains a plaguing 
challenge28. Although NP display beneficial and pharmacological properties, NPs may produce an array 
of toxins, utilised by plants as a mechanism of defence that may not be embraced in the field of drug 
discovery due to its association with adverse side effects and lethal dosage of toxicity29. Some major 
setbacks associated with the use NPs as active pharmaceutical ingredients, include limited oral 
bioavailability and low stability under physiological conditions. The use of  NP also lacks adequate 
synthetic approachability, as NP tend to lack stringent criteria of “drug likeness” following Lipinski’s 
“rule of five30” and related ADME/pharmacokinetic31 criteria (ADME=absorption, distribution, 
metabolism, excretion. Lipinski’s rule of five was first introduced to provide guidelines that synthetic 
chemists could adhere to, to establish better biophysical properties and to ensure optimal bio-active 
drug candidates32.  In the late 1990s the phasing out of NP in drug development was prompted by the 
application of high-throughput screening (HTS)33 of small molecules.  However its use was short lived 
due to the downward trend of potential drug candidates in drug design.  Therefore highlighting the need 
for improvised approaches to accelerate the drug discovery process.  
 
2.5. Harvesting chemical fragments from natural sources in drug discovery  
Prompted by the relentless search for authentic novel lead compounds that could be integrated in the 
development of potential therapeutic drugs, led to resurgence of NPs. At the inception of research into 
natural products, the utilisation of chemically derived fragments harvested from these rich resources, 
rapidly lead to the emergence of innovative strategies towards drug discovery and later, towards the 
replication of these essential compounds34.. The chemical fragments isolated from natural products 
make them a viable option for lead structure in drugs as they display complex chemical diversity35, a 
vast range of biochemical specificity and beneficial bioactive properties which include a broader 
spectrum of molecular property distribution, such as a contrasting molecular mass. The prominent 
structural features of NP, include the eminent presence of chiral centres, with enhanced steric 
complexity. The high presence of oxygen atoms in comparison to nitrogen, sulphur and halogen 
containing groups is also observed in NP, accompanied by generation of resulting OH bond formation. 
From a statistical analytical perspective NP display, a lower ratio of aromatic rings to the sum of the 
heavy atoms, whilst the number of hydrogen-bonds donors that are solvated to those that are acceptors 
displays higher favourability, these properties exhibited by NP differ quiet to distinctively from 
counterparts such synthetic drugs and combinatorial libraries13. With the majority of the rings present 
in the structure of NP, selectively or completely saturated proves advantageous as NP display greater 
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interactivity with an array of proteins and enzymes36. Current therapeutic drugs implement the use of 
less than one-fifth of the ring systems present in natural products. The use of chemical fragments derived 
from  NP in modern pharmacotherapy remains imperative, as clear indications of its importance is 
displayed in its use in a range of an anti-cancer agents, which include  paclitaxel and its derivatives 
from yew (Taxus) species, brentuximab vedotin, vincristine and vinblastine from Madagascar 
periwinkle (Catharanthus roseus (L.) G. Don), and camptothecin; and a range of derived analogs. 
Recently, other classes of compounds such as the epothilones have shown promise in the battle against 
cancer and one of its derivatives37. 
 
However in recent years, despite the obvious importance, there has been a residual decline in the 
isolation of these chemical fragments isolated from NP by pharmaceutical industries. Which can be 
attributed to the relentless process of isolation and limited chemical tractability reduced number of 
newly discovered therapeutic drugs reaching the market, decreasing substantially from that which was 
anticipated38. Other identified obstacles included low stability under physiological conditions and 
limited oral bio-availability12.   
Therefore a new alternative approach for drug discovery is required. Introducing an evolving approach 
encouraging the modification of chemical compounds from natural resources by reducing the size of 
the compound whilst retaining or even enhancing the biological activity exhibited elucidating that size 
does matter39. This unique approach provides an avenue to tailor natural products through synthesis of 
a smaller compounds with essential parts, providing an extraordinary approach to unlock the full 
potential of natural products, producing optimal results with a total reduction in time and cost.   
 
2.6. The “Reduce to Maximum concept” 
The reduce to maximum concept entails the reduction in the size of a chemical compound, whilst still 
retaining or enhancing bioactivity, ensuring better synthetic approachability perpetuating the 
reproduction of essential chemical compounds derived from NP, that would otherwise be inaccessible 
from natural resources. It was first proposed by Crane and collegues34  the approach enables the versatile 
use of these chemical compounds derived from NP and offers a unique platform for the use of NP as a 
major source for innovative drug discovery25.The retention or enhanced activity exhibited by a chemical 
compound that has been drastically reduced in size can be attributed to the compound now being able 
to eloquently position itself within the active size eliminating factors such as, steric hindrance, bulky 
side chains, producing optimal torsional flexibility40. The “reduce to maximum concept” introduces the 
generation of functionally optimized analogues. Their integrated use has led to innovative drug 
discovery in various fields, from biofilm prevention, drug resistance alleviation and neuroengineering41. 
A key example would be the use of Eribulin mesylate, derived analog of  marine sponge Halichondria 
okadai Kadota42 the natural compound Halichondrin B displayed in figure 2.1. The synthetic analog 
CHAPTER 2: EXPLORING NEW AVENUES IN DRUG DISCOVERY “THE REDUCE TO 
MAXIMUM CONCEPT” 
15 
 
displayed synergistic activity as the parent compound, whilst still superseding the desired 
pharmacokinetic properties of the parent compound comprising of a 35% reduction in molecular weight. 
 
 
Figure 2.1.Halichondrin B isolated from marine sponge Halichondria okadai Kadota and its 
structural analog Eribulin42. 
The lack of availability, strenuous synthetic approachability and dose-limiting toxicities associated with 
the natural product Bryostatin isolated from Endobugula sertula, led to the development of picolog a 
structurally simplified analog of Bryostatin. Although being reduced by just 20% from the parent 
compound, the structural analog picolog superseded the biological activity of Bryostatin used in the 
treatment of cardiovascular disease, stroke, pain, or cognitive dysfunction43.  
 
This approach enables the retention of suitable effects in minimized, bioactive scaffolds which can be 
attributed to “fragment likeness” perpetuating a high-degree of similarity29. This reduce to maximum 
concept provides an avenue to overcome the limitations associated with the use of parent natural product 
structural complexity such as lack of accessibility or viable synthetic approachability, poor synthetic 
specificity and low producing yields. In addition this approach may overcome barriers in drug design 
such as drug resistance high levels of toxicity, reduced potency and effectivity, limited bioavailability 
and adverse side effects, providing a viable yet rational protocol that can be followed for next generation 
drug discovery. Enabling the utilization of the most essential fragments of a chemical compound as not 
all constituents of the natural products can be easily synthesized due to high structural complexity 
possessed by NP as well as the high costs associated with its synthesis on an industrial scale. 
Exploitation of the chemical and structural databases which are comprised of a range of diverse yet 
unique chemo types derived from NPs, may facilitate the introduction of new versatile chemical entities. 
 
Amongst the stumbling block encountered with regard to drug design and discovery, drug resistance is 
one of highest contributing factors44. Administration of pharmaceutical drugs for the treatment of a 
range of diseases, may often lead to the tolerance of these disease to the administration of therapeutic 
treatment, resulting in drug resistance. There is a large degree of complexity, escalating from in vivo 
 
 
 
 
 
 
 
 
 
 
 
Halichondrin B Eribulin  
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drug activation, which exhibits an intricate mechanism in which particular substances interact with 
different proteins. The interactions that occur between the target protein or enzymes and the therapeutic 
drugs, result in the modification, degradation and optimally the activation of the drug to perform its 
biological activity. Many anticancer drugs must undergo metabolic activation in order to acquire clinical 
efficacy45. However decreased drug activation may stem from cancer cells as they gradually gain 
resistance to treatment. The distinct prevalence of drug resistance highlighted the dire need to facilitate 
further research for a more permanent solution to the pending life threatening disease. The alarming 
rate of resistance exhibited by a range of cancers  to once effective traditional therapies46 has heightened 
the search for potential drug candidates. The battle against cancer has been one that has been on-going 
for many decades, in more recent times the treatment of various cancers are often associated with 
adverse side effects that may contribute to the reduction in effective therapeutic treatment.  Further 
prevalence of this disease may be attributed to a range of contributing factors such as high levels of 
toxicity and continuous developed resistance47.Thus the search of alternative treatment is a focal point 
in alleviating the burden inflected by this dreaded disease. 
 
2.7. The role of Nucleocytoplasmic transport in cancer pathogenesis 
Studies conducted by the International Agency for Research on Cancer (IARC), estimated 14.1 million 
new cases of cancer observed in the year 2012 globally, of these new cases 8 million  occurred in 
developing countries, which constitute 82% of  the world’s population48 as observed in figure 2.2. The 
dire effects of this pernicious disease is predicted to further impend a devastating burden on a global 
spectrum if it remains incurable, the number of newly emerging cases is expected to rise to 21.7 by the 
year 2030, with 13 million cancer deaths arising from the expansion and aging of the population49. 
 
The burden impended by cancer is one that is being experienced globally, there are wide range of 
resources dedicated towards the research of cancer and the identification of potential onco-targets. It 
has been observed, that the upregulation of nucleocytoplasmic transport is predominantly associated 
with the elevated expression of CRM1 protein. The elevated expression of the CRM1 protein correlates 
with the high incidence of cancers such as ovarian50, pancreatic51,52,  kidney53 and cervical cancers54 as 
well as gastric carcinoma55, glioma56, osteomsarcoma57, leukemia58,59. In addition to mantle cell 
lymphoma60, multiple myeloma61  and melanoma62,63 and a range of others. In 2016 it has surfaced that 
majority of these cancers are some of the most prevalent cases of cancer. Nucleocytoplasmic transport 
upregulation is also associated with drug resistance and stands out as a poor prognosis factor in many 
malignancies64.  
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Figure 2.2. Estimate number of newly emerging cases of cancer cases in 21 world areas, 201265. 
The presence of the cell nucleus distinguishes eukaryotic organisms from prokaryotes, it is enclosed by 
the nuclear envelope and isolated from the rest of the cell66. The nuclear pore complex (NPC) is the 
prominent portal mediating the transfer of proteins or nucleic acid between the nucleus and the cytosol. 
Relatively smaller molecules are freely permeable across the NPC, however to travel through these 
pores, larger molecules such as proteins exceeding a mass of 30KDa are adversely restricted by the 
NPC and are reliant on the reinforcement of transport receptors67. The transport receptors are regarded 
as an alternative mode of transport for these larger molecules or even smaller molecules to be 
transported efficiently in and out of the nucleus. This presence of soluble transport factors called 
karyopherin proteins comprise of these transport receptors68.  
 
There are a wide range of karyopherin proteins encoded by the human genome utilised for transporting 
a set of cargoes (protein or RNA) that comprise of specific sequences/motifs, also known as nuclear 
localization signal (NLS) or Nuclear export signal (NES) or both69. The karyopherin proteins can be 
distinguished as importins or exportins depending on their direction of transport in or out of the nucleus. 
Karyopherin proteins that can mediate both the import and export of molecules are referred to as 
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transportins70. The Karyopherin protein mediate their  mechanism of interaction by directly binding to 
exposed NLS or NES, and then regulate the movement of cargo to the cytoplasm or nucleus71. Dynamic 
nuclear–cytoplasmic Shuttling of specific proteins out of the nucleus is essential for the regulation of 
the cell cycle and proliferation of both normal and malignant tissues. Therefore a dysregulation of this 
fundamental process may alter a wide radius of cellular processes such as gene expression, signal 
transduction, immune response, and cell differentiation, fundamentally leading to the prognosis of 
cancer72.  The crucial role of the CRM1 protein is highlight in nucleocytoplasmic transport, in addition 
to signal transduction, immune response as well as cell differentiation74 (Figure 2.3) 
 
2.8. The role of CRM1: Nuclear export factor  
Chromosome Region Maintenance 1 protein (CRM1), also known as exportin-1 (XPO1), belongs to the 
karyopherin β family75. The exportin CRM1 is a 120 KDa protein and is the most prominent nuclear 
export receptor in the cell.The CRM1 protein mediates the export of cellular proteins and is associated 
with a leucine-rich nuclear export signal (NES, a short 8–15 amino acid hydrophobic motif)59 out of the 
nucleus. The location of gene coding for CRM1 is situated on chromosome 2p15 and is widely 
preserved in a range of species such candida, yeast, drosophila, xenopus, and mammals. The 
evolutionary conserved nature of CRM1 highlights its central role for NES-dependent nuclear export 
of protein complexes76. For a cargo to exit the nucleus, the CRM1 must recognise the nuclear export 
signal (NES), thereafter initiating the cooperative formation of a tight trimeric complex CRM1/NES-
cargo/RanGT. The complex translocates together into the cytoplasm, where RanGTP is hydrolyzed to 
RanGDP by RanGAP42 This decreases the affinity between NES and exportin, causing dissociation of 
cargoes. Bidirectional karyopherins bind to NLS cargoes in the cytoplasm and bind to NES cargoes 
when exiting nucleus, with similar cargo association/dissociation mechanism to importins and exportins 
discussed above50. 
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Figure 2.3. Schematic drawing representing the mechanism of nucleocytoplasmic transport. The steps 
highlighted are of the varying stages involved in the transport between the nucleus and the 
cytoplasm66. 
CRM1 perpetuates the cellular localization of an expanding range of diverse-functioning protein cargos, 
inclusive of many tumour suppressor, cell cycle proteins, and viral proteins. Examples of nuclear 
effectors which are exported into the cytoplasm in cancer include the drug targets topoisomerase IIα77 
and BCR-ABL78 and tumour suppressor proteins such as Rb79, APC80, p5381, p2182 and p2783,74 like 
APC (adenomatous polyposis coli protein), NFAT (nuclear factor of activated T-cells), β-catenin or 
Survivin, Rb (retinoblastoma protein), p53 and Bcr-Abl mislocalize in different cancer cells (Figure 
2.4). Another protein that is dependent on the CRM1 protein for mediated transport is the human 
immunodeficiency virus type 1 (HIV-1) regulatory protein Rev; the NES of Rev is recognized by the 
exportin 1 and transported out of the nucleus. HIV-1 Rev protein moderates the regulation of the HIV-
1 mRNA which initiates the export of un-spliced and partially spliced mRNA25.  The diagnosis of many 
cancers as well as viral and inflammatory diseases can be directing related to the aberrant 
mislocalization of cellular CRM1 cargoes, which may interrupt normal cellular functioning systems84. 
Studies reveal restricting the level on interaction occurring between the CRM1 and proteins  containing 
the NES may provide potential therapeutic benefits that can be utilised in the development of more 
permanent treatment against cancer and other disease conditions85. This can be attributed to cancer cells 
utilizing the  nuclear-cytoplasmic transport system to enable the stimulation of tumour growth and 
simultaneously evade apoptotic processes47  
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Figure 2.4. CRM1-mediated nuclear export highlighting the most prominent cancer hallmarks.      
Proteins in black display direct cargoes of CRM1. Proteins in red, are shown to be suppressed by 
nuclear export inhibition through a diverse mechanism86. 
2.9. Nuclear export inhibitors  
Cognate peptide segments present in protein cargoes to which CRM1 binds are referred to as the 
fundamental nuclear export signals or NESs (commonly known as leucine-rich NESs). The amino acids 
residues that contribute to the NES peptides are regularly spaced conserved hydrophobic residues which 
form a groove situated on the outer/convex surface of the ring-shaped CRM187. The NES peptides 
display an elevated affinity range for the CRM1 protein and are highly diverse in its composition.  NES 
peptides are usually 8–15 amino acids long with regularly spaced conserved hydrophobic residues as 
depicted in Figure 2.588. Data extracted from Sequence, peptide-library, and bioinformatic analyses best 
concluded the description for NESs is a set of six consensus sequences, which differ in the spacing’s 
between four key hydrophobic residues ϕ1, ϕ2, ϕ3, and ϕ482.There are three diverse accessible structures 
for NESs which include cargos extracted from protein kinase A inhibitor (PKI), Snurportin-1 (SNUPN), 
and the HIV1-Rev protein,  all of which are bound to CRM1. 
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Figure 2.5. Representative image of the NES binding groove present on the CRM1 protein displaying 
the essential consensus sequence comprising of hydrophobic residues62. 
2.10. First generation inhibitor- Leptomycin B  
The development of anticancer agents has always been steadily reliant upon the chemical constituents 
harboured by NPs as 60% of anti-tumoural compounds currently on the drug market used for the 
treatment of cancer has originated directly from natural sources. After the first classification as 
antifungal compounds, the potent anti-tumoural activity of Leptomycin was elucidated89,90. The first 
members of the Leptomycin family identified were Leptomycin A and B (LMB) which were first 
isolated from a strain of Streptomyces91. Biological studies further demonstrated the cogent inhibitory 
activity of the CRM1-dependent protein export from the cell nucleus. Figure 2.6 displays the structure 
of LMB, and its bound conformation to the hydrophobic NES binding groove of CRM1. LMB occupies 
the same space as four of five hydrophobic PKIαNES residues (ϕ0, ϕ1, ϕ2, ϕ3, and ϕ4). Displaying its 
mechanism of inhibition as it displaces the essential NES peptides required for binding to the CRM1 
export protein, thus elucidating its broad spectrum of inhibition of nuclear export. LMB  covalently 
modifies chromosomal region maintenance 1 (CRM1; exportin 1) at the nucleophilic sulfhydryl group 
of a reactive Cysteine residue by utilizing its α β-unsaturated ẟ-lactone, thus restricting export of protein 
cargoes that are dependent on this cleft by inhibiting the formation of the ternary CRM1/cargo 
substrate/Ran complex, or the binary complex CRM1/cargo substrate in the absence of Ran76 
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Figure 2.6. (A) Illustrates the structural composition of anti-fungal compound Leptomycin B, (B) 
displays the bound conformation of LMB to the hydrophobic NES binding groove of CRM168. 
The strong dosage-limiting toxicities associated with the administration of LMB lead to minimal 
clinical benefits , resulting in profound anorexia and malaise, which  are potentially off-target effects 
as LMB treated cells permanently retarded nuclear export posing not only lethal for cancer cells, but 
also for normal cells. Although dose-limiting toxicity prevented further development of Leptomycin B  
as an antitumor agent92, Gademann and co-workers41 saw the un-touched potential locked within the   
Anguinomycin core and went on to synthesize Anguinoymcin D, a close structural relative and  derived 
analogues for further studies with the aim of investigating if the polyketide side chain mimics93 the 
hydrophobic leucine-rich nuclear export signal of the cargo protein and is necessary for activity41. 
Anguinomycins A-D were  reported to induce apoptosis in pRB-inactivated tumour cells, mediating 
inhibitory activity of immortalized cells, simultaneously inducing restraint of growth in normal cells, 
therefore limiting the total inhibition of the CRM1. The CRM1 protein plays an essential role in the 
nucleocytoplasmic transport, thus its presence remains eminent within normal cells.  The selectivity 
displayed by Anguinomycin regarding their mode of action still remains unknown94. It was first 
hypothesized by Bonazzi and colleagues to completely omit the polyketide chain present in 
Anguinomycin D to derive the simplified structural analog SB 640. Experimental testing conducted on 
the parent compound Anguinomycin D and analog SB 640 displayed substantially inhibitory activity 
depicted by the analog SB 640 which contains a truncated polyketide chain displayed in Figure 2.7.  
Displaying a minimal reduction in the inhibitory activity as compared to the parent compound 
illustrating a retention of biological activity95.  
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Figure 2.7. Structural comparison of Anguinomycin D isolated from Streptomyces sp. and its 
simplified structural analog Anguinomycin D analogue (were constructed using Chemdraw Ultra96) 
This is not the only experimental study revealing the potent activity of the derived analogue; another 
avid example is demonstrated by militarinone D, truncated to yield structurally simplified analogues 
with improved activity46,41. This hypothesis has97 led to the prediction that truncated chemical structures 
might retain biological activity, as long as some of the key features were still maintained within the 
chemical fragment scaffold.
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CHAPTER 3 
3.0. Introduction to computational chemistry 
  
3.1. Introduction 
Computational chemistry is rapidly emerging as a subfield of theoretical chemistry, where the principal 
emphasis is focused on finding solutions to chemical related problems by employing the use of 
computers. Computational chemistry is not directly involved in developing theoretical methods, but 
rather in obtaining results relevant to chemical problems1. There is nevertheless a strong interplay 
between traditional theoretical and computational chemistry. The integration of computational 
chemistry may enable newly emerging as well as long plaguing problems, to be studied in the search 
for effective solutions. Data extracted from computational integrated calculations may reveal limitations 
and possible suggestions towards suitable improvisations that can be implemented in modern drug 
discovery2. Depending on the accuracy required, and the nature of the system at hand, it is now possible 
to obtain useful information for systems containing up to several thousand particles.  The only limitation 
associated with computational chemistry may be the selection of an appropriate theory or method for a 
given problem, and the ability to evaluate the quality of the obtained results3. There are two standard 
methods emanating from computational chemistry, the first being to study the chemistry of molecules 
at an electronic level, known as quantum mechanics, the second being molecular dynamics, which 
neglects explicit electron treatment and focuses on classical laws of physics. This chapter outlines the 
range of computational and theoretical tools applied in this study.  
 
3.2. Quantum mechanics  
In 1900, German theoretical physicist, Max Plank, inadvertently gave rise to the field of quantum 
mechanics, as he discovered that energy is discharged in small packets (called quanta) and emitted in 
wavelengths4,5. Quantum mechanics is an essential constituent of computational chemistry, enabling the 
prediction of observable chemical properties. The fundamental law of quantum mechanics aims to 
illustrate that microscopic systems can be described by wave functions that capsulate and characterize 
all physical properties of a system 6. Quantum mechanics is the branch of mechanics that focuses on the 
mathematical analysis of the motion and interaction of subatomic particles7, principally dealing with 
the influence of electromagnetic forces on the movement of electrons8.  To perceive the electronic 
behaviour in molecules and consequently of the structures and reaction of molecules, knowledge of 
quantum mechanics, particularly the Schrödinger equation9. By solving the Schrodinger equation in 
quantum chemistry, properties of a system in terms of a wave function can then be extracted. Quantum 
CHAPTER 3: INTRODUCTION INTO COMPUTATIONAL CHEMISTRY 
33 
 
mechanics can be integrated to provide a better understanding and predict large-scale phenomena, 
initiating fundamental calculation of electronic structure and interactions1 
3.3. The Schrödinger equation 
The Schrödinger equation is regarded as the fundamental core of physics, as it entails a descriptive 
analysis of quantum mechanical behaviour within a system10. It was initially introduced by Austrian 
physicist Erwin Schrödinger in 192610. In mathematical physics, the Schrödinger’s equation undertakes 
the same role as the Hamilton’s laws of motion as one of the basic equations in non-relativistic quantum 
mechanics and non-relativistic classical mechanics respectively11,12.  
 
There are two types of Schrödinger’s equation: the first is the time-dependent Schrödinger’s equation, 
this being the most applied equation in computational chemistry13, and defines the Hamiltonian operator 
as the accumulated value of the potential and kinetic energy. The second type is the time-independent 
Schrödinger’s equation14. The simplest form of Schrodinger equation is presented as follows15:  
                         Η𝜓 = Ε𝜓                                                                                          Eq.1 
 
Where H denotes the molecular Hamiltonian, 𝜓 a wave function that expounds the probability of the 
electron and nuclear within disclosed locations, and E depicts the energy of the system (3, 5). The 
molecular Hamiltonian is the sum of the kinetic (T) and potential (V) energy, which can be denoted 
as16:  
                       Η = Τ +V                                                                                         Eq. 2 
Particles are referred to as point masses, under the assumption that relativistic effects are not considered.  
The sum of kinetic and potential energy operators make up the composition of the Hamiltonian, which 
can then be presented in detail as:  
 
                       H = ‒ 
𝒉𝟐
𝟖𝝅𝟐
 Ʃi 
𝟏
𝒎𝒋
  (
𝝏𝟐
𝝏𝒙𝟐
+ 
𝝏𝟐
𝝏𝒚𝟐   
+ 
𝝏𝟐
𝝏𝒛𝟐
)  + ƩiƩ<j (
𝒆𝒊𝒆𝒊
𝒓𝒊𝒋
)                      Eq.3 
Where A and B represents the nuclei: i and j are the electrons, MA depicts the  mass of nucleus A, me 
the mass of an electron, RAB the distance between nuclei A and B, rij the distance between electrons i 
and j, ZA the charge of nucleus A, rAi the distance between nucleus A and electron i17. The 1st term in  
Eq. 3 is the operator of kinetic energy of electrons, the 2nd term is the kinetic energy of the nuclei 
operator, the potential energy of electron-nuclei attractions operator is presented by term 3, the 4th term 
is the operator for potential energy of electron-electron repulsions, and the last
 
term is the operator for 
potential energy of nuclei-nuclei repulsions18. However, the Schrodinger equation integrates a range of 
equations, and hence cannot be resolved for a molecular system other than H2, therefore the  
implementation of the Born-Oppenheimer approximation is considered an applicable solution5. 
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3.4. Born-Oppenheimer approximation 
The Born-Oppenheimer approximation is considered an imperative commodity in finding a solution to 
the Schrödinger equation, where the coupling between the nuclei and electronic motion is often 
omitted19. This enables the nuclear parameters to be taken into consideration when solving the electronic 
part and for the resulting potential energy surface (PES) to be integrated in finding a solution for 
motion20. The Born-Oppenheimer approximation enables the use of the Schrodinger equation for a 
specific molecular system to be distinguished into two equations, namely the electron and nuclear 
equations from which the total energy of the system can be established13. The energy of a molecule is a 
function of the electron coordinates, but depends on the parameters of the nuclear coordinates, which 
define the molecular geometry. As nuclei are fixed, so the nuclear kinetic energy operator is neglected, 
as observed in Eq.4, permitting the statically distribution of electron input within a molecule to be 
determined 21,14. 
                       Telec = − 
𝒉𝟐
𝟖𝝅𝟐𝒎  
 Ʃ𝒊
𝒆𝒍𝒆𝒄𝒕𝒓𝒐𝒏𝒔  (
𝝏𝟐
𝝏𝒙𝟐
+  
𝝏𝟐
𝝏𝒚𝟐   
+  
𝝏𝟐
𝝏𝒛𝟐
)                      Eq.4 
Presented below is the Schrödinger equation for fixed nuclei electrons17 which is incorporated in range 
of computational chemistry software:  
 
              Helec 𝝋𝒆𝒍𝒆𝒄 (r, R) = Eeff (R) 𝝋𝒆𝒍𝒆𝒄(r,R)                                 Eq.5 
 
3.5. Potential energy surface 
The potential energy surface (PES) is a mathematical function that correlates the energy of a molecule 
as a function of its geometry21, thereby enabling a deeper visual insight of structural characterization, 
as derived from the latent relationship of potential energy versus a molecules geometry22.  PES is 
utilized to decipher energy minima, as well as the states of transition that occur within chemical 
reactions, with respect to the position of the nuclei22. The Born-Oppenheimer approximation is invoked 
in molecular systems to generate the PES23. The concept of potential energy surface arises from 
variations in the mass and magnitude of the velocity between electrons and nuclei, a phenomenon 
defined by the Born-Oppenheimer approximation24. The phenomenon of the Born-Oppenheimer 
approximation stipulates the instantaneous variation in the position of the electrons with regard to the 
nuclei displacement, thereby permitting the depiction of potential energy surface, as the potential of 
atoms motion within a molecule or atoms in collision with each other is often referred to as the adiabatic 
motion25,22,26. 
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Figure 3.1. A Graphical representation of a two-dimensional potential energy surface27. 
 
The potential energy surface displays regions of unfavourable electronic interactions as high potential 
energy, as they depict molecular conformations or high-energy nuclear arrangements27, with the regions 
of low energy being used as an indicator to display nuclear interactions presented as low energy 
molecular conformations and accompanied by favourable electronic interactions28. Reactants and 
products are commonly rendered as stable structures, resulting in relatively low potential energy, which 
is often associated with the minima on the PES of a reaction coordinate. Figure 3.1 indicates that the 
minima represents the compounds structure during a state of equilibrium, whereas the first order saddle 
point represents the transition state or activated complex. The saddle point is referred to as an indicative 
factor of particular modifications in nuclear arrangements, which may result in decreased potential 
energy, while the others lead to higher energy.  
 
3.6. Molecular mechanics  
Molecular mechanics (MM) is an approach that permits the parameterization of a simple algebraic 
expression for the total energy of a compound, disregarding the computation of wave function or the 
sum of the electron density29,30. MM is based on the classical laws of physics, which is able to compute 
a molecule’s geometrical and transitional state of equilibrium, as well as its relative energies present 
among conformers15.  In this method, there is an assumption that the electrons will attain their optimal 
position once the position of the nuclei is defined, and are hence not considered explicitly. The Born-
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Oppenheimer approximation forms the basis of the assumption, as it depicts nuclei as heavier than 
electrons, thus making their motion negligibly compared to that of electrons21. 
 
MM is commonly applicable to larger systems, such as those in pharmaceutical and biological fields of 
research as they may exceed the use of more computer-intensive molecular orbital protocols31. The 
application to large systems can be attributed to suitable approximations (and its associated fast speed) 
and ability to determine the molecular conformation, or the atomic arrangement of a molecule, on the 
basis of its structural characterization and relative potential energies32. MM is an empirical method, and 
is reliant on force field parameters that comprise of a range of parameters extracted from experimental 
data. One of the simplest illustrations of MM is that of a-ball-and-spring model of atoms and molecules, 
with classical forces being present between them8. The total energy of a molecule, as defined by 
molecular mechanics, comprises of a range of contributing interactions that includes bond length and 
angles, torsions and non-bonded interactions, such as van der Waals and electrostatic contribution, as 
presented in the equation 633:  
 
               𝑬𝒕𝒐𝒕= 𝑬𝒔𝒕𝒓+𝑬𝒃𝒆𝒏𝒅+𝑬𝒕𝒐𝒓𝒔+𝑬𝒗𝒅𝒘+𝑬𝒆𝒍𝒆c                                     Eq. 6 
 
Where Etot is the total energy, Estr is defined as the bond-stretching energy, and the energy contribution 
from angle-bending is denoted by Ebend. The torsional energy contribution is represented by the term 
Etors, and the terms Evdw and Eelec represent van der Waals and electrostatic energy contributions 
respectively. This equation in complex, with the parameters required to describe the characteristics of 
various molecules being referred to as the force field. 
 
3.7. Force fields  
A force field encompasses a set of functions and constants, defined as parameters, which can be applied 
to correlate the energy of the system in accordance with its particles34. The parameters aim to define the 
reference points and force constants, providing a description of PES for various types of molecular 
systems with contrasting degrees of freedom that result from the inclusion of attractive or repulsive 
interactions between atoms. Force fields such as AMBER35, CHARMM36, NAMD37 and GROMOS38 
display popularity, and are commonly used to set parameters that can be  applied to the simulation of 
biomolecules. The parameters incorporated in force fields are generated from the derivation of the ab 
initio method, or the semi-empirical quantum mechanical calculations. They can also be generated from 
experimental data, such as X-ray and electron diffraction, NMR and neutron spectroscopy39,34. The 
forces acting within a molecule vary with regard to each system, with the administration of each force 
field needing to be adjusted accordingly. The different force fields are associated with a range of 
strengths and weaknesses, relative to the data applied, allowing a particular problem to be dealt with. 
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The moderate low computational cost and accurate prediction protocols incorporated in the use of force 
fields highlights their use as an attractive option is molecular dynamics simulations and molecular 
mechanic calculations40.There are a wide range of force fields that can be applied to a system, the force 
field of choice must be selected cautiously as each force field contains specific parameter that are 
designed for certain families of molecules41. Therefore it is crucial to choose the correct force field as 
it may increase the accuracy and applicability of theoretical structure function of your system of study. 
Force fields can only crudely approximate electrons interaction and hence cannot be used for bonding  
breaking nor formation calculations42. The AMBER force field43 was employed in this study, by 
applying the General AMBER Force Field (GAFF) parameters accompanied by the standard AMBER43 
force field for the protein being introduced.   
 
3.8. Molecular dynamics  
Numerous studies have incorporated a vast range of molecular systems that include organic molecules 
in solution and biological macromolecules44. Molecular dynamics45,46 and Monte Carlo47 simulations 
are two techniques that provide useful insights into the structural, thermodynamic, and, for molecular 
dynamics, dynamical properties of systems in the condensed phase48. Molecular dynamics (MD) is a 
computational technique used for simulating intricate molecular systems at an atomic level, as well as 
for computing the motions of individual molecules49. The application of molecular dynamics is a sought 
after computational tool50, as it enables the fluctuations that may occur in the motion of the system to 
be evaluated over a set period of time. MD enables the kinetic and thermodynamic properties of the 
molecular system to be determined48. The low-energy deformation states derived from the inherent use  
of MD simulations can be incorporated to inspect the conformational space present in a large restricted 
system51,52. If the initial geometry of a system is derived from experimental data stemming from X-ray 
or NMR structures, then MD techniques can be employed for sampling the conformational space53. In 
order to set a MD system for simulation, the force, in combination with the energy of all particles within 
the system, must be calculated54. MD integrates the use of Newton’s equation of motion for atoms on 
an energy surface55.  
 
              Fi = mi 
𝑑2𝑟𝑖 (𝑡)
𝑑𝑡2
                                                                            Eq. 7 
 
3.9. Molecular docking  
Molecular docking is an essential component of computational chemistry, which involves determining 
the most optimal position of two molecules with respect to each other. Molecular docking is utilized in 
structure-based drug design, and is often highlighted as one of the main contributing factors to the 
problems arising in global optimization56.  The dynamic level of interaction displayed between ligand 
molecules and their receptors is often dependent upon the molecular recognition of  the lock and key 
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mechanism57. Docking is often referred to as the positioning of a small molecule, such as an inhibitor 
or drug candidate, often referred to as a ligand, into the active site of macromolecules of known 
structural conformation44. These macromolecules include proteins, such as nucleic acid, receptor or 
enzyme. Docking is performed to generate the optimal conformational pose, as well as to determine the 
crude binding affinity between the protein-ligand interaction58.  Being able to predict the binding of 
small molecules to target proteins plays a crucial role in structure-based drug design, as it enables the 
screening of virtual libraries59 of “drug like” molecules, thereby assisting in next generation drug 
development60.  The ligand-receptor binding energy is calculated as follow61:  
 
               𝑬𝒃𝒊𝒏𝒅𝒊𝒏𝒈=𝑬𝒕𝒂𝒓𝒈𝒆𝒕+𝑬𝒍𝒊𝒈𝒂𝒏𝒅+𝑬𝒕𝒂𝒓𝒈𝒆𝒕−𝒍𝒊𝒈𝒂𝒏𝒅                              Eq. 8 
 
Numerous molecular docking programs are used for academic and commercial purposes62, such as 
Dock63, AutoDock GOLD64,  FlexX65, -+ GLIDE66,  ICM62 , Surflex and others. While each program 
displays sufficient suitability for precise docking, the docking program Autodock generates two-orders 
of magnitude in comparison to other programs, while maintaining substantial accuracy in its binding 
mode prediction67. The docking method used in this research study is the advanced version of 
AutoDock, AutoDock Vina68. The application of molecular docking in this study enabled the 
confirmation of the most optimal binding pose of both compounds Anguinomyicn D and derived analog  
SB 640 in the NES binding groove of the CRM1 protein69 (detailed discussion in chapter 5).The binding 
affinity generated by many docking software’s such as Autodock63, neglect the presence of protons of 
the enzyme and inhibitors, thus the scores generated are often regarded as unreliable. MD takes into 
consideration protons and the solvent often water molecules. Thus MD results generates a more accurate 
binding affinity score as opposed to docking protocols42. 
 
3.10. Thermodynamic calculations 
The embodiment of thermodynamics in computational chemistry enables a deeper understanding of 
chemical reactions, providing a platform to calculate molecular properties and its derived entities, and 
predicts the chemical reactivity.  The essential role of thermodynamic calculations is highlighted, due 
to its current contribution in the field of quantum mechanics, allowing the optimization of geometry 
and calibration. Thermodynamic calculations aid in distinguishing the energy surface associated with a 
particular chemical reaction. The use of thermodynamics can retroactively justify minimization of 
energy, and its interconnection with energy surface may therefore provide ample knowledge based on 
the transition structure and reaction pathways70. Thermodynamic calculations assist in determining the 
binding free energy as an endpoint calculation, which provides indispensable information about the 
binding interaction that occurs between the ligand-protein complexes.  
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3.10.1 Binding free-energy calculations 
Binding free energy calculations are eminent in the ligand-receptor complex formation71,72, and have 
aided substantially in studies that include computational chemistry, thereby providing in-depth 
knowledge about drug design, protein structure determination73 and protein-protein complexes74,75. Two 
popular methods used to estimate the free binding energy with success of small ligands to biological 
macromolecules are the Molecular Mechanics/ Poisson-Boltzmann Surface Area (MMPB-SA) and 
Molecular Mechanics/Generalized Born Surface Area (MMGB-SA) approaches70,76. MM/GB-SA and 
MM/PB-SA rely on molecular simulations of the ligand-protein complex to compute rigorous 
statistical-mechanical binding free energy within a specified force field77. Both approaches display 
favourable use, which can be attributed to their modular nature and lack of calculations that stem from 
training set integrating continuum solvation models merging with molecular mechanics calculations78 . 
Each approach displays avid accuracy and computational effort between the empirical scoring and 
stringent alchemical perturbation methods, and can be compared in order to reproduce and rationalize 
experimental data79. The MM/PB-SA and MM/GB-SA methods are utilised to determine free energy 
decomposition, which can be meticulously ranged into various groups, depending on the groups of 
atoms or types of interactions from which they originated 74,80,  
 
The MM-PBSA employs a more rigorous algorithm than the MM/GB-SA, and simultaneously 
substitutes the MM/GB-SA model of electrostatics in water 81,82. However, with regard to calculations 
incorporating protein-drug interaction ,including carbohydrates83 and nucleic acids 84, the MM-GBSA 
method is favoured over the MM-PBSA 85. The use of binding free-energy calculations can also be 
utilized to enhance the results of virtual screening and the docking of therapeutics drugs58. The binding 
free energy between the ligand and receptor highlighting the MM/GB-SA is given by86:  
              GBIND = GCOMPLEX – GRECEPTOR - GLIGAND                                     Eq. 9 
 
              ΔGBIND = ΔEMM+ ΔGGBSA– TΔS                                         Eq.10 
 
              ΔEMM =ΔEINT +ΔEVDW +ΔEEEL                                                                Eq. 11 
 
              ΔGGBSA = ΔGEGB +ΔGESURF                                                                         Eq.12 
 
where ΔEMM is the molecular mechanics energy of the system in a vacuum, ΔGGBSA denotes the 
solvation free energy, TΔS is the entropy, the sum of the bonded internal energy (ΔEInt) is represented 
by ΔEMM, non-bonded van der Waals (ΔEVDW), electrostatic (ΔEEEL) and ΔGGBSA consists of polar 
contributions accounted for by the generalised born model (ΔGEGB) and non-polar contributions 
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(ΔGESURF)87,88. An additional preference for applying the MM/GB-SA method is due to its potential to 
aid in analysing per residue energy decomposition. 89,90. The dynamic analysis of binding affinity aids  
in  determining the approximate inhibitory activity of each inhibitor91,92. During the MM-GBSA binding 
energy calculation, the correct binding conformation of each ligand can be determined prior to the 
binding energy estimation.93. Herein, ligand-protein binding free energies were predicted using a 
MM/GB-SA approach. 
 
 3.11. PASS toxicity prediction  
High levels of toxicity and adverse side effects displayed by current therapeutic still remains a challenge 
in the field of drug discovery. Therefore, alternative methods are required to improve toxicity prediction 
and safety assessment of potential drug candidates, prior to be being administered in clinical trials.  
Computational methods aim to complement in vitro and in vivo toxicity tests to potentially alleviate the 
burden associated with animal testing ultimately diminishing high associated expenses and time 
constraints. Incorporating the use of computational tools may permit the assessment of the toxicity 
profile of a chemical compound prior to synthesis.  
  
The in silico tool referred to as PASS (Prediction of Activity Spectra for Substances)94 is an integral 
resource that can be utilised to predict a spectrum of biological characteristics of a chemical fragment. 
PASS is an online based in silico prediction tool, it initiates the prediction of the biological activities of 
selected chemical compounds, their mechanisms of action and related levels of toxicity interacting with 
a single or a range of biological targets within an organism94. The proposed in silico prediction tool 
establishes the activity of a chemical compound based on the chemical constituents of the chemical 
fragment which extends further to reveal novel biological activities of selected phytochemical leads, 
their bioactive constituents and related side-effects95.  
 
The current version of PASS encompasses the prediction capacity of over 3750 pharmacological effects, 
biochemical mechanisms of action, specific toxicities levels and metabolic terms on the basis of 
structural formulae of drug-like substances with average accuracy >95%. Results obtained from the use 
of this in silico tool has been validated with the application of in-vitro as well as in-vivo assays, the 
results obtained from these studies correlate to those predicted by PASS online software94. The PASS 
online prediction was performed for parent compound Anguinomycin D and analog SB 640 (results are 
presented in chapter 5) 
 
3.12. Homology modeling  
In the midst of newly developing diseases, the crystal structure of a target protein is of utmost 
importance in the field of drug discovery and development96. While various techniques can be utilised 
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to generate the structure of macromolecule, which include the use of as X-ray crystallography, NMR 
spectroscopy and electron microscopy, they are often associated with multiple pitfalls. Homology 
modeling is gradually emerging as the sought after tool to be used to construct 3D macromolecule 
structure, as it is done with  ease and accuracy in comparison to the other techniques97. Homology 
modeling enables the construction of a proteins structure by using its sequence as a reference template, 
of which the X-ray crystal structure is known. An accurate homology model depends on the existence, 
detection and quality of the known template structure from which it will be modelled. Although high-
resolution structures are optimally extracted through X-ray crystallography, this approach is associated 
with a high cost increment, considerable experimental time and many trial runs98. Furthermore, some 
biologically important macromolecules lack X-ray crystal structures or high resolution 3D- structural 
properties, with reference to their protein sequence, the implementation of homology modeling resolves 
this challenge. An essential aim of drug discovery is to contrive bioactive molecules that are intended 
to target the disease condition, with minimal side effects, and hence are beneficial to the patient. The 
3D structure of the target protein is a fundamental factor to obtaining full characterisation and exhibition 
of the mechanism of interaction on a structural and molecular level, elucidating the mode of action 
(MOA) of a drug molecule, and hence, greatly facilitate drug design. This study provides a precise 
protocol that can be followed for homology modeling to generate a protein model of high accuracy that 
can aid in developing therapeutic drugs.  The role and application of homology modeling in next 
generation drug discovery is presented in Chapter 4. 
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4.1. Abstract  
The continual evolution of the world is chaperoned by the emergence of new diseases, which presents 
itself at every turn therefore determining the 3D structure of a protein drug target becomes a crucial 
factor in the process of drug discovery and design. The 3D structure of a protein plays a critical role 
when establishing the functional domain of a protein, enabling the structural dynamic interactions with 
specified ligands and proteins to be studied and understood on a molecular level. The essential role of 
Homology modeling also regarded as comparative modeling, is described in this review as its use 
enables the provision of low-resolution structures that may aid molecular biologists, and pharmaceutical 
scientists with considerable insight regarding the spatial conformation of important residues within the 
protein structure providing a template for the design of new innovative drugs. This reviews provides a 
conclusive route map of the process of homology modeling that can be followed, accompanied by 
technical guidelines and tools that can be utilised. This review highlights the features of each tool 
enabling the construction of the most accurate model that may aid in next generation drug discovery.  
4.2. Introduction 
There has always been a steadfast focus on the field of drug design and development, focusing on 
structural biological studies of protein-drug interactions1,2. Understanding the underlying mechanism 
of protein-drug interaction is pivotal, as it provides insight into the structural features that are prominent 
for ligand affinity3, drug specificity and optimization during these interactions4,5 to ultimately  ensure 
optimal effectivity of the therapeutic drug. The continual use of homology modeling for the generation 
of three-dimensional (3D) protein structures6 has molded the way to develop docking and structure-
based virtual screening protocols,7. These 3D generated models are being sought after to gain intricate 
information behind the mechanism of interaction between drug-protein complexes such as binding 
mode analysis8. In addition, they provide indispensable insight into a protein’s 3D structural and 
mechanistic molecular functions. In the last decade, homology modeling has transitioned into the most 
popular in silico tool for generation of three-dimensional (3D) structures of molecular targets 9,10. 
Homology modeling also known as comparative modeling uses homologous sequences with known 3D 
structures for the modeling and prediction of the structure of a target sequence11,12.   
Due to the combined efforts of experimental structural biologists and genomics, an increasing fraction 
of protein families has at least one member with a known experimental structure present in the Protein 
Data Bank (PDB)13,14. This is accompanied by the development of sensitive and precise HMM profile 
methods15, prompting researchers to grasp the availability of sequence information to aid in the 
detection of remote template relationships16. The recent advances in homology modeling, distinctly in 
identification and alignment of reference sequences in relation to the template structures, distant 
homologues, modelling of loops and side chains, 3D model optimisation and validation contributes 
substantially to the consistent prediction of a protein’s structure which were not possible even several 
years ago10, 17,18.  The core essence underlying the use of homology modelling to predict the 3D structure 
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of a protein relies on the use of the target sequence to be used in comparison to other known structures 
(the templates), this  notion implies that similar sequences (evolutionary related)  display similarity in 
their structures10. 
 A crucial role of homology modeling amongst many others has been the generation of 3D molecular 
targets of cancer19 in a bid to develop and discover effective therapeutics drugs to attenuate this 
malignant disease20.Recent studies, highlight the utilization of homology modeling for the construction 
of the 3D structure of RNA-dependent RNA-polymerase of the Ebola virus21 elucidating the 
instrumental role of homology modeling in drug discovery22. Another key example of the development 
of new drug targets constructed utilizing homology is the NS5 protein of the Zika virus which has been 
identified as a global health threat by the World Health Organization (WHO)23. Current technologies 
such as X-ray difractometry24 and Nuclear Magnetic resonance (NMR) are utilized for experimental 
illustration of the 3D structure of a protein 25, however these tools are associated with a range of 
limitations such as an increase in cost and  time consumption26, 27. Despite prominent advances in X-
ray crystallography, NMR spectroscopy, and a wide range of other structural identification tools, the 
lack of newly emerging 3D protein structures, still remains a challenge in drug discovery. The potential 
use of homology modeling for the generation of these missing protein 3D structures is an attractive 
option as its use is often associated with low-cost and time effective protocol28. 
This review provides intricate information of some of the most popular homology modeling tools and 
software’s that have been utilized for over a decade. It also highlights the essential role homology 
modeling has played in the drug discovery research along with some of the challenges that maybe 
associated with its application. In addition this review provides technical guidelines that can be 
incorporated to achieve the most accurate model. This review also provides a clear outline of the protocol 
of homology modeling and steps that can be followed, presented in Figure 4.1.  
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Figure 4. 1. General Protocol of 3D Protein Model generation by Homology Modeling 
 
4.3. Protocol of Homology Modeling 
There is a standard protocol of homology modeling which is adopted, with minor variations occurring 
in the validation and optimization steps of homology modeling. Homology modeling procedure consists 
of the following steps: 
 
4.3.1. Template recognition – Comparative modeling is initiated by the identification of at least a 
single protein29, with a known 3D experimental structure, that is in relation to the target sequence 
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serving as  the template sequence30,31. A protein’s 3D structure may be largely determined by its amino 
acid sequence as proteins from the same homologous line display greater conservation in their 3D 
structure in comparison to their amino-acid sequences32, 33, 34,35,36. Elucidating similarity between two 
proteins which may be detectable at sequence   level, and may therefore imply shared structural 
similarity among these proteins 37,38. 
The target sequence is rendered as the query sequence in the search of template sequences against 
databases such as PDB (Protein Data Bank)39 for known protein structures using the target sequence as 
a query. A search is conducted as each structure in the database is compared to that of the target 
sequence. If the target sequence is not known, popular algorithm tools such as BLAST (Basic Local 
Alignment Search Tool) which incorporate the pairwise sequence-sequence comparison40, structural  
protein sequence databases such as GenBank41 NCBI36,  protein database FastA42, or protein 
identification resource UniProt43 can be utilized  to search for structures in the data banks of amino acid 
sequences that could be compared to the target sequence. The accuracy and validity of the generated 
3D structure is largely dependent upon the sequence similarity of the template sequences in relation to 
the target sequence 44,45. Sequential identities >25% suggest that the template and target have similar 
3D structures and, therefore, the template is appropriate for modeling46,10,34. However, sequence 
similarity greater than 25% is the minimum requirement for generating useful and accurate models47,48.  
Once suitable templates have been identified, a comprehensive literature search must be undertaken on 
the chosen template sequences, analysing all the entities of the sequence inclusive of its biological role 
and relation to the target sequence49,50. Apart from choosing a template sequence with a high sequence 
similarity, there are various factors that must also be taken into consideration when selecting an 
appropriate reference template. These factors include selecting templates that are derived from similar 
phylogenetic tree to the target sequence51,52 which may aid in the correct selection of template sequences 
which are in close relation to the target sequence resulting in the most accurate 3D model being 
generated 53 .  
Other factors include assessment of environmental34 parameters such as pH54,55 solvent 44, and  identified 
ligands 10,18  of the template sequences in comparison to the target sequence. This must be accomplished 
when selecting the most appropriate templates as it ensures the most optimal conditions are adhered for 
the generation of an accurate target model 48. The E-value (Expected value) 56 is also referred to when 
selecting the most appropriate templates to be used, as the closer the E-value is to zero the greater 
similarity amongst the templates ensuring overall accuracy. Template selection may also be based on 
multiple alignment as the use of multiple template sequences may increase the accuracy of the 3D 
protein model34. The refinement of the experimental structure is another essential factor when selecting  
a template, such as the resolution and the R-factor of a crystallographic structure57, inclusive of the 
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number of restraints per residue for an NMR structure58 as it is indicative of the template sequence 
reliability and precision.   
4.3.2. Template Alignment – Once the most suitable reference templates have been identified, 
alignment is performed which integrates a specialized method to align the template sequences to the 
target sequence55. Local alignment is referred to as the alignment of the query sequence to the substring 
of the target sequence59, whereas global alignment involves the use of substrings of both sequences 
during alignment60. Local alignment is performed to aid in the detection of possible templates 61,  
whereas global alignment is used for model construction62.  
It has been observed that for closely related protein sequences with a greater percentage similarity than 
25% there is pronounced accuracy observed during alignment and thus renders it appropriate for 
modeling63,64,65,66. There is an increased observation of misplaced gaps, representing insertions or 
deletions which cause residues to be misplaced in the template ultimately leading to alignment errors, 
commonly occurring in models that are generated from sequences with a low sequence similarity. 
However alignment errors are the main cause of deviations in comparative modeling even when the 
correct template is chosen67.  Elucidating the essential role of sequence alignment as a crucial step in 
homology modeling and thus the quality of sequences to be aligned is of utmost importance and is an 
indicative factor of accuracy of the generated 3D model68. Multiple alignments can be used when more 
than one template is available. This approach proves advantageous as it increases the spectrum from 
which the target 3D protein can be modelled69,31 providing more options to model bad-aligned regions 
and affords a model reflecting the mean values among all templates31. Careful inspection and adjustment  
on automatic alignment may improve the quality of the modeling51,70. There are a wide range of 
programs that are utilized for sequence alignment such as PSI-BLAST40 which aligns the target 
sequence to a sequence profile constructed from multiple alignment of members derived from a protein 
family. Further advancement of this class of methods is to align two sequence profiles37 such as the 
FFAS71,72 and SALIGN73,45.  Alignment accuracy improves as one progresses from one generation of 
the profile methods to another 74,55. 
5.3.3. Model building - Proceeding the target-template alignment, the next step in homology modeling 
is model building. Table 4.1 displays useful tools and services that can be used for model building, 
some programs presented are also able to generate loop and side chain regions of the 3D model. There 
is a versatile range of methods that can be utilized to build a protein model one these methods is the 
rigid-body assemble method75. This method dissects various conserved regions of the protein such as 
the loop regions which anchors the proteins and the side chains which decorate the backbone of the 
protein model. This method is based on natural dissection enabling the construction of a protein model,  
by assembling the framework of  a small number of rigid bodies, extracted from the aligned template 
protein structures76,1, 36,77.  
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Table 4.1. Popular Tools or Services used for Homology Modeling 
 
Homology modeling  
Tools or Services 
Description 
 
 
 
Links 
CPHmodels Is a web-server that is able to predict a 3D protein structure from a 
single template homology model This server employs a novel  
remote homology-modeling algorithm incorporated in the hybrid 
scoring functions of the CPHmodels-2.0 78,79 
http://www.cbs
.dtu.dk/service
s/CPHmodels/ 
MODELLER Is a comparative modeling tool that constructs 3D protein structures 
based on spatial restraints. MODELLER is able to generate a 3D 
protein model from the provision of an aligned  sequence with 
known related structures44,80 
http://www.sali
lab.org/modell
er/ 
 
SWISS-MODEL 
Is a fully automated protein structure homology-modeling server. 
User-friendly web interfaces. The SWISS-MODEL template library 
provides annotation of quaternary structure and essential ligands   in 
combination with co-factors to assist in the construction of precise 
structural models, inclusive of oligomeric structure. This server 
makes considerable use of model quality estimation for selection of 
the most suitable templates and provides approximation of the 
expected accuracy of the resulting models. SWISS-MODEL only 
requires an amino acid sequence input81, 82, 83, 84 
http://swissmo
del.expasy.org/ 
Phyre2 This remote homology modeling utilizes a range of detection tools 
to build 3D models. Special features include prediction of ligand 
binding  as well as analysis  of variants among the amino acid 
sequence of a protein sequence 85. 
http://www.sbg
.bio.ic.ac.uk/ph
yre2/html/page
.cgi?id=index 
Pcons.net PconsM, an automated protocol that uses single templates to build 
protein models, whereas PconsM utilizes multiple templates to 
generate a protein model.  PconsM is implemented as a separate 
extension to this pipeline that is run when the internal and external 
predictions by Pcons.net are completed, and updated as soon as 
there are new alignments available86. 
http://pcons.net
/ 
HHpred HHpred generates 3D models based on pair wise comparison of 
profile hidden Markov models (HMMs) from a single or multiple 
query sequence.  HHpred displays high sensitivity when generating 
homology models and searches a range of alignment databases such 
as Pfam or SMART( different from other software’s that use 
Uniprot) 87. 
http://toolkit.tu
ebingen.mpg.d
e/hhpred 
 
LOMETS 
Local Meta-Threading-Server) is an on-line web service that 
incorporates spatial restraints to construct 3D protein structures. 
This server generates the model via collection of high-scoring 
target-to-template alignments from 8 locally-installed threading 
programs (FUGUE88 HHsearch, MUSTER, PPA, PROSPECT2, 
SAM-T02, SPARKS, SP3). 
http://zhanglab
.ccmb.med.umi
ch.edu/LOME
TS/ 
Robetta Develops both ab initio and comparative models of protein 
domains. By using the ROSETTA fragment insertion method89. 
http://www.rob
etta.org/ 
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This server is able to construct full-length with the use of a domain 
prediction method 90,90 
Chunk-TASSER A protein structure prediction method that integrates threading 
templates from SP3 and ab into folded chunk structures, and 
displays great accuracy when modeling difficult targets91,92 
http://cssb.biol
ogy.gatech.edu
/skolnick/webs
ervice/chunk-
TASSER/inde
x.html  
 
PSiFR 
Provides a vast range of tools for protein tertiary structure prediction 
and structure and sequence-based function annotation. Incorporates 
a range of protein structure prediction methods such as TASSER, 
TASSER-Lite and METATASSER 
http://psifr.cssb
.biology.gatech
.edu/ 
Protein Model Portal 
(PMP) 
The PMP displays a unique interface highlighting the structural 
features of a protein. PMP offers interactive services for model 
building and quality assessment81,93 
http://www.pro
teinmodelporta
l.org/ 
ProModel  
ProModel generates 3D protein structures either from a reference 
template or a defined template, allowing comprehensive analysis of 
the target protein such as the active site and channels. ProModel 
possesses a built-in roamer library able to generate side-chain 
conformation38 
http://www.vlif
esciences.com/
products/VLife
MDS/Protein_
Modeller.php 
SCWRL4 SCWRL is ranked amongst the best homology modelling tools due 
to its speed, accuracy, and ease-of-use. It uses a backbone-
dependent rotamer library. Due to its speed and accuracy it is an 
attractive tool specializing in  generation of side chain 
conformations 94 
 
http://dunbrack
.fccc.edu/scwrl
4/index.php 
 
 
IntFOLD 
The IntFOLD server is a novel independent server and  provides a 
unified interface for Tertiary structure prediction/3D modeling, 3D 
model quality assessment, Intrinsic disorder prediction, Domain 
prediction, Prediction of protein-ligand binding residue 95. 
http://www.rea
ding.ac.uk/bioi
nf/IntFOLD/  
PSIPRED The PSIPRED is a simple and versatile model construction tool, 
incorporating two feed-forward neural networks which perform an 
analysis on output obtained from PSI-BLAST 96. This server 
performs scalable biological analyses97. 
http://bioinf.cs.
ucl.ac.uk/psipr
ed 
PEPstrMOD Performs prediction for structure of peptides containing natural and 
non-natural/ modified residues. The Pepstr server predicts the 
tertiary structure of small peptides with sequence length varying 
between 7 to 25 residues98. 
http://www.imt
ech.res.in/ragh
ava/pepstr/ 
PROTEUS2 
 
 
 
PROTEUS2 bundles signal peptide identification, transmembrane 
helix prediction, transmembrane b-strand prediction, secondary 
structure prediction (for soluble proteins) thus highlighting its role 
as an avid homology modeling tool. It incorporates all this into a 
single prediction pipeline99,100. 
http://wks1633
8.biology.ualb
erta.ca/proteus
2/ 
Jpred The Jpred server can utilize either a single protein sequence or 
multiple sequence alignment and generates a predicted model based 
on the Jnet algorithm101 
http://www.co
mpbio.dundee.
ac.uk/jpre) 
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Other methods include segment matching where comparative models can be constructed by utilising a 
subset of atomic positions such as the Cα atoms from template structures as “guiding” positions in a bid  
to identify and assemble short, all-atom segments that correlate to these guiding positions 103. The search 
for all-atom segments that may correlate with the  conformational search restrained by an energy 
function 18 it can also be obtained with the use of segment matching program SEGMOD34,86 which 
incorporates a generalized method for modelling of 3D protein structures.  
Comparative modeling by satisfaction of spatial restraints is one of the most popular methods used for 
model building, which is performed by computer program MODELLER104,80,49, this method is initiated 
by generating a range of constraints derived from the structure of the target sequence105.  
The restraints are generated based on the corresponding distances between aligned residues in the 
template and the target structures assuming that their structures share structural similarity106,44. These 
derived restraints are usually determined by stereo-chemical restraints on bond lengths, bond angles, 
dihedral angles, and non-bonded atom contacts that are obtained from molecular mechanics force 
field107. Minimization is performed on the infractions of all the restraints in order to optimise the 3D 
protein model. The last method utilized is the modeling of the protein structure using artificial evolution. 
Once the backbone of the 3D protein model is generated it is followed by loop and side-chain modeling. 
4.3.4. Modeling loops – Homologous proteins have gaps or insertions in sequences, which are often 
referred to as loops. However the structure of the loops are not conserved throughout evolution and are 
regarded as the most variable regions of a protein where insertion and deletion often transpire108. The 
loop structure predominantly determines the functional specificity of a protein structure and plays an 
essential role in the active and binding site of a protein109. The accuracy of loop modeling is a crucial 
factor in determining the validity and adequacy of homology models for analysing protein-ligand 
complex interactions110. The generation of loops is necessary to connect the sections within the protein 
and are generally much shorter in length in comparison of the whole protein chain77. Thus prediction of 
the loop structure is a complex process as the loop structure exhibits greater structural variability than 
strands and helices111. There are two widely used methods that are implemented for the construction of 
the loops. These methods include database-search approach or conformational search methods112. The 
data-base search approach scans all known protein structures to find segments accommodating the 
pivotal core regions44. These methods provide accuracy and efficiency, but may also be associated with 
limitations such as the number of possible conformations vary as the length of the loop increases113. As 
a result only 4-7 residues long have their conformations present in the protein structure databases.  
3D Robot 3D Robot is a new algorithm that generates decoys of the protein 
structure integrating free fragment assembly accompanied by 
supplemented with hydrogen-bonding inclusive of compact 
interactions102. 
http://xhanglab
.ccmb.med.umi
ch.edu/3DRob
ot 
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The second method is the ab initio114 approach also known as the conformational search approach which 
relies on the optimization of a scoring function 55. The search strategies include the minimum 
perturbation method115, molecular dynamics simulations116, genetic algorithms5, Monte Carlo 117 and 
simulated annealing 60.Loop prediction by optimization is applicable to both simultaneous modeling of 
multiple loops in combination with the generation of loops interacting with ligands. Although this is a 
complex process, it is much easily constructed using the ab-initio method as compared to the data-base 
search approach34,  118, as fragments are extracted from unrelated structures with different environments. 
4.3.5. Side-chain modeling – Side-chain modeling is an important step of homology modelling. 
Side-chain prediction usually involve the addition of the chains onto fixed backbone coordinates, either 
obtained from template structures or generated from ab initio modeling119 simulations or a combination 
of these two methods120. Protein side chains tend to exist in a limited number of low energy 
conformations called rotamers121,102. In side-chain prediction methods, rotamers are selected based on 
the preferred protein sequence and the given backbone coordinates, by using a defined energy function 
and search strategy. The side-chain quality can be analysed by root mean square deviation (RMSD)122 
for all atoms or by detecting the fraction of correct rotamers found123. Table 4.2. Presents tools that can 
be used for loop and side chain modeling.  
 
Table 4.2. Tools used for Loop and Side Chain Modeling  
Loop and Side Chain Modeling Tool Link  
Loop Prediction  
COILS  http://www.ch.embnet.org/software/COILS_form.html 
CONGEN http://www.congenomics.com/congen/doc/index.html 
Side-Chain Prediction   
RAMP  http://www.ram.org/computing /ramp/ramp.html 
SWCRL  http://dunbrack.fccc.edu/SCWRL3.php 
 
4.3.6. Model optimization – After constructing a model the next step is the optimization in order to  
eliminate or minimize unfavorable interactions between non-covalently bonded atoms124. This is 
usually performed by energy minimizations protocols such as molecular dynamics simulations125,63 
using force fields, implementing avid restrictions in order to avoid excessive deviations from the 
original templates and, therefore, loss of the experimental configuration of the model 30. 
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4.3.7. Model validation – the quality of the predicted model can determine the functionality of the 
model and the amount of data that can be extracted. Thus the accuracy of the model is of utmost 
importance. The model can be evaluated as a whole or validated based on various segments of the 
structure117. Determining whether the model has the correct fold is one of the key essential steps in 
validation. The H-factor126 resembles the role that the R-Factor plays in X-ray crystallography. It stems 
from the basics of homology modeling and it incorporates all data that were included in the model 
building protocol to evaluate its accuracy in addition to checking for good stereochemistry.  A correct 
fold will be established if the most optimal template is utilized for the generation of the model in 
accordance with precise template alignment. A high sequence similarity increases the assumption that 
the correct fold has been constructed85. This can also be attributed to a significant Z-score as well as 
retention of essential functional or structural residues in the target sequence. Once the correct fold has 
been accepted, a more detailed analysis can be conducted on the 3D protein model.  Apart from 
sequence similarity playing a crucial role in accuracy as mentioned, the environment influences the 
accuracy significantly as the structure of a protein determines its functionality within a designated 
environment.  
The stereo-chemical analysis of the protein structure is a basic requirement. Some popular programmes 
specialising in determining the stereochemistry of the generated models include WHATCHECK127,55 
and PROCHECK128,129. Stereo-chemical analysis of the model’s consistency is evaluated in a similar 
manner in which experimental structures are performed. This is according to parameters like the 
distribution of the torsional angles ϕ and ψ from the main chain130,131 and the distribution of the rotational 
angles of side chains132, in order to fix eventual experimental and interpretation errors133, 134. Residues 
with stereo-chemical problems will fall in non-permitted regions of the Ramachandran plot135, 56. The 
ideal model should present more than 90% of the residues within the permitted regions of the 
Ramachandran plot 130. 
Other programs focus on determining spatial features of the 3D protein model, based on 3D profiles 
and statistical potential of mean force. These programs include VERIFY3D 136,137 and PROSAII138,139. 
These programs pay substantial attention to environmental parameters in which the model was 
constructed in respect to the expected environment. Table 4.3 comprises of validation tools that can be 
utilized when evaluating the validity of the generated 3D model. Model that’s have been generated 
utilising homology modeling can be further assessed  in a biannual large-scale experiment known as 
the Critical Assessment of Techniques for Protein Structure Prediction, or CASP140. 
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Table 4.3. Tools used for Homology Model Validation  
 
Validation Tool Description  Link  
 
PROCHECK 
Stereochemical property analysis which includes 
bond length and angle, torsional angles and 
chirality of residues141 
http://www.biochem.ucl.ac.uk/
~roman/procheck/procheck.ht
ml 
 
WHATCHECK Analysis of the models Stereochemistry,  analysis 
of nomenclature, symmetry, identification of 
missing atoms or bonds142 
 
http://www.swift.cmbi.ru.nl/gv
/whatcheck/ 
VERIFY3D  Analysis of model compatibility within a 
designated environment prioritizing the analysis of 
residue interaction143 
http://www.doe-
mbi.ucla.edu/Services/Verify_
3D or 
http://nihserver.mbi.ucla.edu/V
erify_3D 
PROSAII Focuses on regions in the model that may have 
been incorrectly folded, as well as incorrect regions 
of the structural model144, 145 
http://www.cam.sbg.ac.at 
Molprobity MolProbity is a web based 3D structure validation 
service that evaluates the quality of a structure at 
both the global and local levels. Includes steric and 
geometric analysis146.  
http://molprobity.biochem.duk
e.edu/index.php?MolProbSID=
7h23k0a4ji0t4ecvmpbtbeoje5
&eventID=2 
 
VADAR  
Volume, Area, Dihedral Angle and Reporter 
Utilises 15 different algorithms and programs for 
protein structure analysis including quantitative 
and qualitative assessment 
http://vadar.wishartlab.com/V
ADAR 
Bioinformatics 
Toolkit  
Integrates a broad spectrum of interactive protein 
bioinformatics analysis147 
http://toolkit.tuebingen.mpg.de  
 
 
4.4. Applications of Homology Modeling  
Homology modeling plays a focal role in the process of structure-based drug design and its importance 
is vastly becoming more evident as the number of available crystal structures increases.  
The function of a protein is dependent upon its motion and conformational changes that may occur148. 
In order to fully understand the molecular mechanism of a protein, a concise description of versatile 
functional states that the protein structure can adopt dynamically must be established8. Some examples 
include allosteric conformational changes on binding events, identification of drug-binding cavities 149, 
86, intermediate excited states on reaction cycles, transport and motion phenomena150, 151. Thus  
elucidating the pivotal role that homology modeling plays in exploring these alternative conformations, 
generating a better understanding behind protein dynamic transitional changes 152, 153, 154.  
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Homology modeling is a formidable application that has not only benefited many spectrums of drug 
design but has also enhanced our understanding on various other aspects that impact drug discovery 
such as analysis of mutations within the active site155, 156 and assessing their biological role in the disease 
state70. Homology modeling has also been found to play a crucial role in compound optimization 102 
Typical applications of a homology model in drug discovery require a very high accuracy of the local 
side chain positions in the binding site. There are a substantial number of 3D protein structures arising 
from homology modeling over the years. Targets have included antibodies 157, multiple proteins 
involved in human biology and medicine158. Homology modeling also plays a crucial role in structure-
based virtual screening for drug discovery7. Figure 4.2 displays the many applications of homology 
modeling in drug discovery.  
Figure 4.2. Range of applications stemming from Homology Modeling accompanied by various 
Protein targets-orange of each application 
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Employing the insight extracted directly from the 3D structural details of a drug target may 
constitute an accurate account of the drug-protein interaction, providing an acute perspective 
on the mode of action (MOA) of the drug molecule which may further advance the process of 
drug design and discovery. Utilization of accurate 3D protein structures may ensure drug-target 
specificity and effectivity, which is an eminent requirement in all fields of drug design. 
Although homology modeling plays a pivotal role in drug discovery, there are minor hiccups 
associated with its application that must be overcome. These challenges along with possible 
solutions are summarized in Table 4.4 
Table 4.4. Challenges and possible solution associated with Homology Modeling 
 
Challenges associated 
with Homology 
Modeling 
Possible Solutions towards generating an accurate homology 
model 
Reduced accuracy  Improving the accuracy of the model, might encompass optimization 
techniques in side chain modeling as well as loop modeling. 
Modeling of 3D Protein 
structures with low 
sequence similarity to 
other templates  
Use of multiple templates, which may ultimately lead to the larger 
coverage of the target sequence 
The use of multiple 
templates can led to 
deviations in the 
alignment thus leading to 
problems associated with 
convergence 
Use of multiple templates that are derived from similar phylogenetic 
tree as that of the target sequence eliminates this challenge  also the use 
of multiple templates alleviates the need for free modeling and thus 
increases the quality of the target protein   
Homology models are 
sometimes considered 
incorrect 
This may not be applicable if the homology model can be compared to 
a structure that spans the entirety of the target sequence 
Alignment errors are the 
main cause of deviations 
in comparative modeling 
Careful inspection and adjustment on automatic alignment may 
improve the quality of the modeling51 
 
4.5. Conclusion  
A rising number of publications have established homology modeling as a fast, trustable, and very 
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useful tool to access consistent 3D models for proteins in which experimental structures are not 
available. The main aim of homology modeling is to predict a structure from its sequence with an 
accuracy that is similar to the results obtained experimentally. Homology modeling provides a feasible 
cost-effective alternative method to generate models. Homology modeling studies are fastened through 
the use of visualization technique, and the differential properties of the proteins can be discovered. 
Advances in structural biology obtained using homology models substantiates the robustness and 
reliability of the software available today to build models. The recent advances in a range of software 
with improvements in the algorithms for alignment, modeling loops and side chains, detection of errors 
and validation of models, have made possible the prediction of proteins structures that, until recently, 
were a remote possibility. Today it is quite clear that with the appropriate software and templates, very 
consistent models can be built utilising this innovative tool. Models generated utilising homology 
modeling have effectively contributed to the field of drug design and development, and from the looks 
of it, homology modeling will continue to be a strong defender against the war on infectious diseases 
where X-ray crystal structures of drug targets are unavailable.
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5.2. Abstract  
This study aims to give  molecular insight into the activity of chemical fragments obtained from natural 
sources, elucidating how the reduction in their structure, may be a contributing factor to retention or 
enhanced biological activity, reduced structural complexity as well as an overall exhibition of desired 
pharmacophore activity displayed. All of which are key aspects of drug design and development. 
Natural compounds have timelessly been a choice in drug design and development however due to 
factors such as limited bioavailability and strenuous synthetic protocols, manipulation of the chemical 
structures obtained from these natural compounds are vastly becoming the new approach in drug 
synthesis.  In a bid to understand and validate the newly established concept of "reduce to maximum” 
highlighting the truncation of  a chemical compounds structure  derived from natural sources, molecular 
dynamic ensembles were generated to obtain per-residue energy decomposition footprints as well as 
thermodynamic integrations as previously introduced in our publications.  From the simulations it can 
be seen that the activity of the analog SB 640 derived from its parent compound Anguinomycin D 
displayed a slight decrease in binding affinity in comparison to the parent compound although being 
reduced by more than half of the C skeleton the analog still displays retention of activity due to the 
presence of the α, β-unsaturated ẟ-lactone moiety, in accordance with experimental data. The analog 
SB 640 also displayed reduced toxicity in comparison to the parent compound with improved chemical 
tractability and a significant reduction in the number of synthetic steps.  
Keywords: Chemical fragment; Natural products; Anguinomycin D; Analog SB 640; Pharmacokinetic 
properties; MD simulation,   
 
5.3. Introduction  
Despite prominent advances in drug design and development, there has been a decline in the 
advancement of new drugs, threatening new therapeutic advances as well as commerciality of drug 
companies. With factors such as limited resources and adamant time constraints, the discovery of viable 
lead drug candidates is still an ongoing challenge in the field of drug development1. The transition of 
screening hits to the actual selection of potential drug targets is a task that requires both discernment as 
well as expertise2,3,4,5. Other underlying factors that influence the observable rise in the incidence of 
prevalent diseases can be attributed to the lack of potential drugs, limited bioavailability or accessibility 
of potential drug sources and lack of expedient synthetic approachability 6,7,8. 
Drug resistance also plays a pivotal role in the observed increase in prevalence. It has been reported 
that between 44000-98000 annual deaths , an estimated 7000 deaths were due to drug resistance and 
adverse drug response caused by harmful side effects of drugs, lack of effectiveness, as well as the  
administration of interacting drugs often leading to toxicity 9.  
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Natural products encapsulate the wisdom of evolution as their derivatives have timelessly been sought 
after on a molecular level due to their pivotal role in biological processes, elucidating their contributing 
efforts in the advancement of human quality of life and healthcare10. Natural products have also been 
highlighted as the ideal starting point in drug discovery due to their ability to selectively and optimally 
bind to the target proteins11,12. Natural products tend to have a high binding affinity to protein targets 
whilst still maintaining constant entropy with limited loss and are still being sought after due to their 
flexibility of adopting different conformations in aqueous and lipophilic environments13.  
The structural diversity and beneficial therapeutic properties possessed by compounds obtained from 
plant derivatives as well as other various natural sources including marine organisms and 
microorganisms, inaugurate their inherent use in the development of pharmacological drugs thus 
unravelling a new era of drug design14,15,16. Chemical fragments isolated specifically from natural 
products have made a resurgence over the past 10 decades in the field of drug development due to the 
exiguous amount of innovative and effective drugs emerging from the field of pharmacological drug 
research and design17,18. Currently, over 50% of new drugs being synthesized by pharmaceutical 
companies are derived directly from secondary metabolites obtained from natural products. 19 
Compounds isolated from natural sources were not the first option in drug design due to the inability to 
determine their chemical tractability, as well as the inability to adhere to the stringent criteria following 
Lipinski’s “rule of five”20  and related ADME (absorption, distribution, metabolism and 
excretion)/pharmacokinetic aspects, which all led to the phasing out of natural products in the 
production of next generation therapeutics21,22. Although there are ample amounts of chemical 
fragments derived from natural compounds that are currently being used in drug development, there are 
still evident pitfalls as they lack adequate effectivity, reduced solubility and display observed 
toxicity23,24,25. 
However recent advances in technology in both organic and computational chemistry have initiated a 
vital transition with the use of synthetic organic chemistry, allowing the traceability of complex 
chemical structures of natural products which has been used to design simplified structural analogs with 
retained biological activity, enhanced biological properties, reduced toxicity, as well as an overall 
reduction in the number synthetic steps 26,27. Such advances have allowed the modification and synthesis 
of compounds derived from natural resources to develop more potent drugs. The biological evaluation 
of the structural intricacy of natural products exemplifies the importance of reducing the chemical 
structure of a complex natural product in order to generate an analog structure for drug discovery 
28,29.This process involves the reduction of unwanted fragments of natural products that are contributing 
factors to the lack of effectivity and toxicity. This may result in retention of essential fragments required 
to induce biological activity. Such strategic process may also aid in providing favourable structurally 
simplified compounds that can be easily manipulated.30 Analysis of drugs and recognition of target 
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proteins through computational modeling and drug design tools may provide vital insight and guidance 
into the design of pharmaceutical drugs31. This could aid substantially in understanding the effect of 
structure reduction of compounds derived from natural resources and how it may further enhance 
optimal pharmacodynamics and desired pharmacokinetic properties essential in drug synthesis. 
 
5.3.1. “Reduce to maximum Concept”  
A study performed by Crane et al.32 encompassing the “reduce to maximum concept” reported the use 
of fragments derived from natural compounds denoting a significant decline in molecular weight, 
structural intricacy as well as reduced number of synthetic steps all of which contributed to the overall 
increase in biological activity thus indicating potency and effectivity14. Derived compounds from 
natural products typically possess a large molecular weight, encompassing a large structure that may 
not be directly involved in the biological activity exhibited by the compound33. This large structure of 
natural compounds may also be a contributing factor to the observed toxicity quintessentially displayed 
by natural compounds34,35. Such structure may also induce inhibition or suppression of the biologically 
active fragment of the compound from exhibiting its full potent effect. A contributing factor could be 
the limitation of the flexibility of the fragment altering optimal binding at the active site of the 
receptor36,37 Simplified analogs derived from natural products may however bind to the target protein 
at more optimal orientations and conformations due to the reduced molecular size,  enabling the ligand 
to direct itself eloquently into the receptor’s active site where it undergoes various internal 
conformational alterations, such as torsion angle rotations and translations38. The reduced size of the 
ligand may allow an adequate fit into the binding site illustrating  improvement or retention of binding 
affinity and chemical specificity39. 
 
A key example would be the use of Eribulin mesylate, a synthetic analogue of Halichondrin B isolated 
from the marine sponge Halichondria okadai Kadota40. The synthetic analog displayed synergistic 
activity as the parent compound, however still superseding the desired pharmacokinetic properties of 
the parent compound comprising of a 35% reduction in molecular weight, requiring only half the 
number of synthetic steps to retain the potency elucidating its key role as an avid cancer treatment 41. 
Another study encompassing the use  of anti-malarial drug artemisinin and its structural analogues 
displayed comparable in vitro anti-malarial activities of the structural analogs as compared to the parent 
compound and  were furthermore effective in animal models 42, 14.  
 
Analog (SB 640) derived from parent compound Anguinomycin D displayed a 60% reduction in 
molecular weight in comparison to the parent compound presented in Figure 5.2 14 Biological studies 
conducted on Anguinomycin D isolated from Streptomyces cerevisiae revealed that this natural 
compound exhibited inhibition of the chromosome maintenance region 1 (CRM1), a 120 KDa protein 
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that plays a crucial role in nucleocytoplasmic transport, in addition to signal transduction, immune 
response as well as cell differentiation43,44. Studies conducted on CRM1 isolated from several organisms  
which include human, mouse, fungi C. thermophilum and S. cerevisiae, the architecture of CRM1 
appears conserved across these homologs19,45,46. The nuclear export signal (NES)-binding groove of 
CRM1 is responsible for binding to NES peptides that direct proteins out of the nucleus mediated by 
the CRM1 export pathway43,47. The NES-binding groove consists of five hydrophobic PKIαNES 
residues (ϕ0, ϕ1, ϕ2, ϕ3, and ϕ4 ) to which the NES peptide fragments in protein cargoes attach to the 
CRM1 for transport out of the nucleus48. Excessive levels of CRM1 in the cytosol have been linked to 
cancer, either inactivation of its tumour suppressive function or an excess of anti-apoptotic activity 
(onco-protein)49,44. In addition, aberrant CRM1 mediated transport results in the further prognosis of 
disease state which include cancer, viral and anti-inflammatory diseases47,50. Inhibition of CRM1 is an 
activity shared by close structural relative of the Anguinomycin family, Leptomycin B, however studies 
on this compound were abandoned due to its elevated levels of toxicity19. Natural compound 
Anguinomycin D exhibits remarkable biological activity which includes induction of inactivated 
retinoblastoma protein (pRB) glia cell death and in the process, pRB is inactivated all of which are key  
points in cancer progression and development.32 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. The crystal structure of CRM1 inhibitor Anguinomycin A (magenta) in complex with 
CRM1-RAN-RANBP1; CRM1-meduim blue, RAN-orange, RANBP1-yellow 
Biological assays conducted by Gademann and colleagues illustrated biological activity retention by 
the synthesized simplified analog SB 640 of Anguinomycin D, displaying a substantial decrease in 
molecular weight, presence of one stereo-center and reduced unsaturation10, thus displaying a 
substantial significance of reducing the structure of a chemical compound to generate smaller and more 
optimally functioning compounds that surpass or retain the biological activity of the parent compound10.  
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Experimental studies conducted by Bonazzi and colleagues illustrated retention in the biological activity 
of the simplified structural analog (SB 640) as compared to the parent compound19. Due to lack of 
resources and in a bid to reduce time constraints, the SB 640 poses as an optimal choice in synthesis 
and effectivity in comparison to the naturally derived parent compound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 2. Structural comparison of Anguinomycin D isolated from Streptomyces sp. and its 
simplified structural analog Anguinomycin D analogue (were constructed using Chemdraw Ultra51) 
In this study, we apply computational approaches to validate the “reduce to maximum concept” and 
provide further insight in determining which fragments of the parent compound can be truncated, as 
well as to aid in the synthesis of smaller and more concise compounds which exhibit a higher degree of 
potency and effectivity. Understanding the mechanism behind the latter concept may also aid in further 
development of next generation therapeutics. 
We also aim to determine if the reduced compound will generate a lower binding affinity as opposed to 
the parent compound, as an evaluation of the total energy of interaction between the therapeutic drug 
and target may be minimal, in order to ensure full and adequate efficacy of the therapeutic drug.  
Computational tools such as molecular docking and thermodynamic calculations render this an easy 
task as it advances the analysis of the level of interaction between the drug-protein complexes, ensuring 
adequate determination of the binding affinity. A computational approach may also aid in determining 
which fragment of the chemical structure is essential for biological functionality and which fragment 
can be truncated in order to ensure optimal activity and retention or enhanced potency. 
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There are various computational tools that cogently estimate ligand binding affinities with an extent of 
precision and efficacy52. Molecular dynamics simulation (MD) is identified as a key computational tool 
utilized in the theoretical inspection of biological molecules53,54. MD simulations provide intricate 
information on the fluctuations and conformational changes that may occur during drug-protein 
interactions.55 Application of molecular dynamics enables the distinctive identification of highly 
contributing amino acid residues based on thermodynamic calculations incorporating per-residue 
energy decomposition technique. This approach allows the identification of highly contributing amino 
acid residues towards the total binding energy in this study MD simulations were performed for 
Anguinomycin D and analog SB 640 each in complex with CRM1. Post MD analyses were further 
performed on the respective systems including thermodynamic calculations to determine binding free 
energy contributions of the parent compound Anguinomycin D and the analog SB 640-CRM1 systems.  
Substantiating the role of MD and thermodynamic calculations in order to understand the structural 
composition, dynamics and thermodynamics of biological molecules of each system. It is also utilized 
to further identify commonly shared amino acid residues  that contribute substantially  towards the total 
binding energy of each system The RMSD, RMSF and Rg of each system were also determined as well 
as the predicted toxicity profile of each compound.   
 
5.4. Computational Methods 
5.4.1. Systems Preparation 
The crystal structure of CRM1 in complex with Anguinomycin A was obtained from the Protein Data 
Bank, PDB code: 4HAV48. UCSF Chimera56 was used to observe and manipulate the crystal structure, 
where chains A and B, H2O molecules, Mg atoms, Cl atoms and a phosphoaminophosphonic acid-
Guanylate ester (GNP)  as well as Anguinomycin A were removed.   
The ligands Anguinomycin D and derived analog SB 640 were drawn using ChemDraw Ultra 9.0 51. 
Each ligand was individually analysed in MMV57, Chimera 56 as well as Gaussview 5.0 58software to 
ensure the correct angle bonds and hybridization were visible. The ligands were individually minimized 
incorporating the steepest descent method and MMFF94S force field in Avogadro59. Receptor 
modification visualization was accomplished using Chimera56 and MMV 57,60,61.  
 
5.4.2. Molecular Docking  
Molecular docking aims to provide the most energetically favourable binding pose as the ligand 
positions itself within the binding cavity of the target protein. Molecular docking was performed using 
AutoDock 62a well-established docking program. Autodock Vina62 was used to generate the calculations 
obtained from the docking scores. During the process of docking, Geister partial charges were added 
whilst Autodock atom types were defined using the Autodock Graphical user interface supplied by 
MGL tools.63 The Lamarckian Genetic Algorithm was applied to determine the docked conformations, 
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a docking technique that is considered rather reliable and adequate64,65. Raccoon 62software was used to 
convert the files into pdbqt format in assembly for docking66. The gridbox was defined using Autodock 
Vina with the grid parameters being X = -32.777, Y = 72.797 and Z = 32.985 for the dimensions and X 
= 36, Y = 30 and Z = 30 for the center grid box67. Molecular visualization of the docked complexes was 
conducted using Chimera software and the LigPlot68 program.  
 
5.4.3. Molecular Dynamic Simulations  
MD simulations were performed on four systems: a parent compound Anguinomycin D-CRM1 
complex; derived structural analog SB 640-CRM1 complex, docked Anguinomycin A-CRM1 complex 
as well as the original complex of Anguinomycin A bound to CRM1 retrieved from the RSCB Protein 
Data Bank. Using the GPU version of PMEMD incorporated in the Amber 14 package, MD simulations 
were conducted for these systems 69, 70. Protein systems were modelled using the standard AMBER 
(FF99SB) force field71 present in the Amber 14 package. The LEaP module of Amber 14 was employed 
to add hydrogen atoms and counter ions to aid in the stabilisation of the system70. Optimisation of 
ligands was performed by addition of partial atomic charges, which were calculated encompassing the 
restrained electrostatic potential (RESP)59,60. Neutralisation was achieved by the addition of Na+ ions 
which were performed on all systems. Atomic partial charges comprising of General Amber Force Field 
(GAFF) were prompted by the ANTECHAMBER module72. Complete solvation of the systems was 
attained within a TIP3P waterbox consisting of a buffering distance of 8 Å in the midst of water and the 
protein surface at box extremity.73  Long-range electrostatics interactions were performed adhering to 
the particle mesh Ewald (PME) method administered in the Amber 14  package with a van der Waals 
limitation of a distance of 10 Å.  
Systems were subjected to consecutive partial partial minimization and full minimization steps. Initial 
energy minimization with a 500 kcal/mol Å2 restraint potential related to the solute, were performed 
incorporating the steepest descent method for 1000 iterations which were finally followed  by 1000 
iterations of conjugate gradient minimization. MD simulations were carried out for 10 ns during which 
the system was heated moderately between a range of 0-300K regulated with the aid of the Langevin 
thermostat74. Systems were equilibrated at 300K under 1 atm pressure whilst retaining force constraints 
on the restrained solute for 500ps prior to production runs, followed by removal of restraints and 
maintenance of a constant pressure (1 bar) using a Berendson barostat.75 All atoms covalently bound to 
a hydrogen atom were subjected to the SHAKE algorithm throughout the MD simulation.76 From 
experimental studies, the preferred pH of the system was at 6.6 which was kept constant and validated 
in accordance with data projected from the H++77 tool which computes the pKa value of ionisable 
groups.78 All simulations were run at a 2 fs time step and the SPFP precision module. Trajectories were 
saved and analysed every 1 ps. The root mean square deviation (RMSD)79, root mean square fluctuation 
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(RMSF)80 and radius of gyration (Rg)81 were calculated using the PTRAJ and CPPTRAJ modules found 
in the Amber 14 package. Results were analyzed and plotted using Origin software82. 
 
5.4.4. Thermodynamic calculations 
Thermodynamic calculations assist in determining the binding free energy as an endpoint calculation 
which provides indispensable information about the ligand-protein interaction. There are various 
computational tools used in the coherent determination of binding affinities namely thermodynamic 
integration (TI)83, free energy perturbation (FEP)84, Molecular Mechanics Generalized Born Surface 
Area (MM/GB-SA)85, Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PB-SA)86, linear 
response (LR)87, and fluctuation-dissipation theorem (FDT)78,79. All these methods provide meaningful 
insight, however there is a generated focus on the MM/PBSA and MM/GBSA methods as they are more 
computationally efficient and encompass a versatile range of parameters for each energy term. The 
MM/PBSA and MM/GBSA methods are employed to calculate binding free energies for 
macromolecules integrating continuum solvation models merging with molecular mechanics 
calculations86. The MM/GB-SA and MM/PB-SA methods are applied to determine the binding free 
energy estimation whilst the MM/GB-SA method presented in Figure 5.3 is employed to establish the 
per-residue energy decomposition of the highest contributing amino acid residues to the total binding 
free energy88,89  
 
Figure 5.3. The different computational approaches used to determine binding affinity, highlighting 
the MM-GBSA approach 
Egas denotes the gas-phase energy; Eint indicates the internal energy; and Eele and EvdW are the Coulomb 
and van der Waals energies, respectively. Egas is determined incorporating the FF99SB force field 
terms. The solvation free energy, denoted by Gsol, is a direct contribution of the polar and non-polar 
states where the polar solvation contribution GGB can be further calculated by resolving the GB 
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equation. The contributing value of the non-polar solvation can be approximated directly from the  
Solvent-accessible surface area (SASA) estimated using a water probe radius of 1.4 Å. TS subsequently 
correspond to temperature and total solute entropy. In order to determine the individual amino acid 
contribution towards total binding free energy between CRM1 and parent compound Anguinomycin D 
and derived analogue SB 640 a decomposition analysis of the interaction energy for each residue was 
computed by using the MM/GBSA binding free energy decomposition protocol in Amber 14 package. 
 
5.4.5. PASS Toxicity Prediction  
Compound toxicity may result from a series of interactions that may occur in relation to a range of 
biological targets within an organism. Toxicity can be characterized by an interaction with a single 
target or from a range of interactions with a versatile group of targets within an organism. Therefore 
determination of  the toxicity of a particular  chemical compound remains an intricate process.90 The 
online tool PASS (Prediction of Activity Spectra for Substances)91 incorporates an in-silico approach 
that generates the predicted biological activities of selected chemical compounds, their mechanisms of 
action and related levels of toxicity interacting with a single or a range of biological targets within an 
organism. PASS prediction is based on the analysis of the chemical compounds structure 
relative to the biological activity exhibited for about 60 000 biologically active compounds92,91. The Pa 
and Pi values vary from 0.000 to 1.000 and the probabilities Pa +Pi≠1 are calculated independently. 
The selected structures of Anguinomycin D and SB 640 were generated using ChemDraw Ultra 9.0.51 
The sdf files were then submitted for toxicity prediction in the PASS online programme.  
 
5.5. Results and Discussion 
5.5.0. Post MD analysis 
Post MD analysis is utilized to analyse the results obtained from Molecular dynamic 
simulations. It can be used to understand the relation between protein secondary structure and 
internal motions59. 
5.5.1. Validation of docking  
Molecular docking validation is pivotal as it ensures the ligand is in an accurate conformational pose as 
it binds to the active site of the target protein. This can be established by validating the grid box size 
and coordinates center along the binding pocket. During the process of molecular docking, the size and 
center of the coordinates of the grid box where the ligands bind must be validated to ensure certainty 
that the correct conformation pose is established93. In a bid to validate our docking approach, we 
removed Anguinomycin A from the crystal structure of CRM1 in complex with RAN-RANBP1 (PDB: 
4HAV) and re-docked it into a low energy structure of the same active site. The docked Anguinomycin 
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A conformational pose was similar to that of the crystallographic pose with an RMSD less than 0.05 Å, 
implying that the applied AutoDock docking parameters were conducive for this system. A 
superimposed image of the crystallized complex along with an energy-minimized structure are 
presented in the supplementary material (S4) implying that the protocol implemented during 
simulations are of adequate reliability and genuine authenticity. 
5.5.2. Root mean square fluctuation 
The biological properties of a protein may be reliant on its physical interaction with other molecules, as 
exhibited upon ligand binding and dissociation that may induce conformational changes essential to a 
CRM1 function. Root mean square fluctuation (RMSF) is calculated to determine the mobility of 
individual residues within a protein59. Figure 5.4 displays the RMSF of Anguinomycin D and analog SB 
640-CRM1 complexes over the 10 ns simulation. 
 
 
Figure 5.4. RMSF of Anguinomycin D-CRM1 and derived analogue SB 640-CRM1 complexes. 
 
The average RMSF values of Anguinomycin D and SB 640 are 1.34 Å and 1.29 Å respectively, 
exhibiting a slight difference of 0.057Å. Both systems displayed rigid stability throughout the 
simulations. From visual inspections, there is evident residue fluctuation predominantly in non-binding 
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residues. The structural and active site residues display minimal fluctuation throughout the simulation 
of the two-systems, substantiating that the binding activity of analog SB640 may be analogous to that 
observed from the parent compound Anguinomycin D whilst displaying marginal perturbation in the 
stability of the protein backbone.  
 
5.5.3 Radius of gyration 
The radius of gyration (Rg) measures the thermodynamics and kinetics of protein folding and may aid 
in determining the compactness and stability of protein complexes94. Figure 5.5 displays the radius of 
gyration of Anguinomycin D and analog SB 640 both in complex with CRM1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Radius of gyration of C-alpha atoms of Anguinomycin D-CRM1 and analog SB 640-
CRM1 complexes 
The Rg of Anguinomycin D and analog SB 640 complexed with CRM1 was determined at 300 K. From 
the conformational analysis, the Rg of both systems displayed significant difference with an average 
Rg value of 37.18 Å for the parent compound Anguinomycin-CRM1 complex as compared to the 
analog-CRM1 complex which was 37.00 Å. SB 640 displays reduced fluctuation of 0.18 Å in 
comparison to Anguinomycin D in complex with CRM1, depicting an overall stable SB640-CRM1 
system as opposed to the parent Anguinomycin D-CRM1 system. The analog SB 640 displayed reduced 
stability during the time interval of 0-2000 ps as opposed to the parent compound, showing that 
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Anguinomycin D-CRM1 complex reached stability much earlier in the simulation as opposed to the 
analog. However between 3500-8000 ps the Anguinomycin D-CRM1 system displayed minimal 
stability in comparison to the analog SB 640-CRM1 system. The observed decline in the Rg may be 
attributed to the hydrophobic interactions presented in Figure 5.7 as the analog SB 640 positions itself 
within the active site of CRM1 protein resulting in a system displaying greater stability.  
5.5.4. MM/GBSA Binding Free Energy Calculations  
Binding free energy calculations were computed using the MM/GBSA protocol. MM/GBSA 
calculations are based on molecular dynamics simulations of the receptor-ligand complex and hence 
are intermediate in both accuracy and computational effort between empirical scoring and precise 
alchemical perturbation methods95,96. This method determines the magnitude of the binding affinity of 
the  contributing amino acid residues.97,39 . The calculated binding free energy (ΔGbind) of the parent 
compound Anguinomycin D and analog SB 640 in complex with CRM1 are -35.10 kcal/mol and -29.13 
kcal/mol respectfully.The analog SB 640 displayed a minimal reduction of  ̴ 6 Kcal/mol , this is in great 
correspondence with experimental studies conducted whereby the analog displayed a marginal 
decrease, however managed to retain biological activity comparable to that displayed by the parent 
compound19. Despite drastic simplification and total reduction in the polyketide chain of Anguinomycin 
D and SB 640, the structurally simplified analog (SB 640) still displayed high activity which can be 
attributed to the essential presence of the α, β-unsaturated ẟ-lactone moiety. From a synthetic 
perspective, the synthesis of the analog SB 640 is reduced by 60% thus resulting in a gain of time as 
well as resources. From previous studies conducted on natural products, a reduction of more than one-
half of the Carbon  skeleton often leads to complete loss of bioactivity19. However, from the binding 
energy exhibited by SB 640 and experimental studies conducted, this has proven to challenge this 
concept, introducing the possibility of a drastic reduction in the total number of synthetic steps as well 
as retention of biological activity. The calculated van der Waals contributions (ΔEvdW) to the total 
binding free energy in the Anguinomycin D-CRM1 complex (-40.83 kcal/mol) are higher than that of 
the SB 640-CRM1 complex (-29.35kcal/mol). The observed van der Waals interactions between the 
parent compound and CRM1, as presented in Figure 5.6, can be attributed to the presence of a 
polyketide chain consisting of a carbonyl group at C17 and hydroxyl group at C18, which is totally 
omitted in SB 640. Although there was a drastic reduction in size of the analog SB 640, the electrostatic 
interactions (ΔEelec) of SB 640 was -11.95kcal/mol superseding that of the parent compound 
Anguinomycin D which was -4.11kcal/mol. From Table 1, it can observed that the electrostatic force 
between the analog SB 640-CRM1 complexes is greater than that of the Anguinomycin D-CRM1 
system with electrostatic forces of -11.95±7.03 kcal/mol and -4.11±5.08 kcal/mol respectively. The 
difference in the electrostatic forces between these systems can be attributed to the ability of SB 640 to 
optimally position itself deeper within the hydrophobic binding groove of the CRM1 protein as opposed 
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to the conformational pose taken by the parent compound Anguinomycin D presented as depicted in                                                                                                                                                                                                                                                                                                                        
Figure 5.6.   
 
Table 5.1. MM/GBSA binding free energies 
Hit                                           Energy Components (kcal/mol)  
Rank                       ΔEvdW               ΔEelec               ΔGgas             ΔGsolv            ΔGbind  
Anguinomycin D   -40.83±3.48      -4.11±5.08     -44.94±6.38     9.84±4.71     35.10±3.28 
Analog SB 640       -29.35±3.18     -11.95±7.03     -41.94±7.80   12.16±5.77    29.13±3.49 
  
Figure 5.6 presents Anguinomycin D bound to the NES binding groove of the CRM1 protein.  
 
Anguinomycin D displays higher van der Waals contributions to the binding of the NES binding groove 
of CRM1. This is due to the presence of the polyketide chain which consists of a carbonyl group at C17 
and hydroxyl group at C18, absent in the analog SB 640.   
 
 
Figure 5.6. 3D structure of Anguinomycin D in complex with CRM1 showing interactions with 
binding site residues 
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Figure 5.7 presents the analog SB 640 bound to the NES binding groove of the CRM1 protein. The 
minimized structure of the analog SB 640, in which the polyketide chain is omitted allows the analog 
to eloquently penetrate much deeper into the groove within the hydrophobic binding groove of the 
CRM1 as presented in Figure 5.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 . Representative structure for analog SB 640 in complex with CRM1 Anguinomycin D 
with 2D and 3D graphical representation of the different binding forces. 
5.5.5. Per–residue Energy Decomposition Analysis  
Per-residue energy decomposition enables the analysis of the protein-drug interaction establishing the 
highest contributing amino acid residues towards the total binding energy. Analysis of the most 
energetically favourable residues highlighted major contributions from amino acid residues Leu 536,  
Thr 575, Val 576 and Lys 579 favoured by van der Waals forces in combination with electrostatic 
interactions commonly shared amongst both ligands. Electrostatic forces aid in inhibitor molecules 
gaining binding energy, contributing substantially to the overall total binding energy. Amino acid Lys 
579 provided favourable electrostatic energy contributions of -1.282 and -2.583 Kcal/mol to the total 
binding energy, which can be observed between Anguinomycin and analog SB 640 CRM1 bound 
complexes respectively. From experimental studies Cys 539 is highlighted as an essential hot spot 
residue, which plays a pivotal role in the binding of potential inhibitors to the NES binding region of 
CRM1. However from MM/GBSA calculations, Cys 539 displayed relatively less favourable energy 
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contributions of 0.05 and 0.50 kcal/mol towards the binding of Anguinomycin D and analog SB 640 to 
CRM1 respectively. Underlying factors such as conformational plasticity and steric repulsion explain 
why molecular modelling of Anguinomycin D and related analogs into a rigid NES-binding groove may 
be different from that depicted in experimental studies. As steric repulsion between certain atoms pairs, 
may be intimately related to the chosen functional form for the non-bonded energy. Another 
contributing factor may be the balance between the functional form and the angle bend/torsional terms 
ultimately affecting the shape, conformation and reactivity of the conformational pose of the ligand as 
it fits itself within the active site of the target protein. 
The NES peptide fragments in protein cargoes are essential as they attach to the CRM1 for transport 
out of the nucleus and restriction of the NES peptide fragments would result in limited transportation 
of onco-proteins out of the nucleus49,50. Natural compound Anguinomycin D occupies four of five 
hydrophobic PKIαNES residues (ϕ0, ϕ1, ϕ2, ϕ3, and ϕ4) at the NES binding site, whereas analog SB 
640 being reduced 60%, occupies three of the five PKIαNES residues despite its massive reduction size. 
Extensive inhibition of the NES groove of CRM1 is attributed to the ability of inhibitors to overlap and 
occupy the majority of the groove displacing the residing NES peptides, thus explaining the extensive 
spectrum of nuclear export blocking exhibited by Anguinomycins and its derivatives.  
 
Table 5.2. MM/GBSA per-residue energy decomposition 
Residue        ΔEvdw                 ΔEele                     ΔGpolar solv             ΔGnon-polar solv          ΔGbind 
Lys 525   -0.304 ±0.264       0.306±0.868         0.060±0.900        -0.051±0.057         0.011±0.219 
                -0.002± 0.001       0.111±0.112        -0.100±0.112         0.000±0.000         0.009±0.002a 
Ile 532     -1.350±0.319        0.206±0.137        -0.065±0.169        -0.152±0.040        -1.362±0.303 
                -0.402±0.190       -0.083±0.081         0.101±525           -0.025±0.020        -0.410±0.194a 
Lys 533   -1.071±0.475        0.063±3.657         0.477±3.439        -0.233±0.114        -0.764±0.452 
                -0.040±0.010        0.224±0.383        -0.157±0.380         0.000±0.000         0.026±0.015a 
Leu 536   -1.925±0.43         -0.013±0.122         0.152±0.112        -0.467±0.071     .  -2.253±0.469 
                -1.401±0.352       -0.150±0.268         0.356±0.315        -0.311±0.057        -1.506±0.334a 
Cys 539   -0.002±0.062       -0.046±0.053         0.089±0.056        -0.005±0.008        -0.045±0.063 
                -0.544±0.325       -0.069±0.518         0.239±0.378        -0.115±0.030        -0.499±0.298a 
Val 540   -0.089±0.07         -0.053±0.055         0.094±0.062        -0.009±0.017        -0.058±0.084 
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                -0.205±0.225        0.020±0.142        -0.009±0.138       -0.048±0.061         -0.241±0.281a 
Phe 572   -2.579±0.531        0.038±0.274      0.831±0.222        -0.368±0.058        -2.259±0.454 
                -0.489±0.163        0.051±0.138      0.117±0.162        -0,093±0.034        -0.415±0.135a 
Thr 575   -1.172±0.476       -0.261±0.921      0.119±0.619        -0.232±0.066        -1.543±0.646 
                -0.520±0.237        0.281±0.350     -0.178±0.310        -0.085±0.047        -0.503±0.241a 
Val 576   -1.496±0.405       -0.050±0.270      0.080±0.213        -0.141±0.029        -1.606±0.439 
                -1.173±0.365        0.158±0.123     -0.013±0.144        -0.118±0.028        -1.146±0.351a 
Lys 579   -1.745±0.303      -1.231±1.071       2.010±1.081        -0.316±0.041        -1.282±0.453 
                -2.227±0.464        -7.538±3.989     7.572±3.432        -0.392±0.053        -2.583±0.771a 
Phe 583   -0.440±0.208         -0.067±0.076      0.240±0.090      -0.095±0.053        -0.362±0.195 
                -1.379±0.367        -0.278±0.202      0.616±0.233      -0.194±0.043        -1.234±0.343a 
 
a   SB 640 
The highest contributing amino acid residues towards the total binding energy of the Anguinomycin D-
CRM1 complex. Substantial energy contributions were evident from residues Phe 572, Leu 536, Val 
576, Thr 575 and Ile 532, contributing -2.26, -2.25, -1.61, -1.54 and -1.36 kcal/mol to the total binding 
energy respectively (Figure 5.8). Phe 572 is identified as the energetically favourable residue with a 
substantial energy contribution of -2.259 Kcal/mol. Its functional aromatic ring forms a hydrophobic 
interaction with the carbonyl group present on the aromatic ring present in Anguinomycin D. Lys 579 
is another energetically favourable residue as the charged NH group of Lys 579 interacts with C1 and 
C13 atoms present in the Anguinomycin D. Contributions from residues Thr 575 and Ile 532 were 
generated through hydrophobic interactions with Anguinomycin D presented in Figure 5.8.  
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Figure 5.8. Per-residue energy decomposition contributions of Anguinomycin D. 
Its functional aromatic ring forms a hydrophobic interaction with the carbonyl group present on the 
aromatic ring present in Anguinomycin D. Lys 579 is another energetically favourable residue as the 
charged NH group of Lys 579 interacts with C1 and C13 atoms present in the Anguinomycin D. 
Contributions from residues Thr 575 and Ile 532 were Amino acids Leu 536, Thr 575, Val 576, and Phe 
583 all contributed substantially with electrostatic and van der Waal forces to the total binding energy 
observed between analog SB 640 and CRM1 complex presented in Figure 5.9. Lys 579 is identified as 
an energetically favourable amino acid residue, with a significant electrostatic energy contribution of -
2.583 Kcal/mol to the total binding energy. The charged NH group of Lys 579 interacts with the terminal 
carbon atoms present in the analog SB 640 as present in Figure 5.7.  
 
 
 
 
 
 
 
Figure 5.9. Per residue energy decomposition contributions of Analog SB 640. 
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5.5.6. PASS Toxicity Prediction  
Prediction of activity spectra for substances (PASS)98 is an online software tool that can be utilised to 
generate the predicted spectrum of a compound’s potential biological activity in addition to predicted 
toxicity and computes it as probable activity (Pa) and probable inactivity (Pi). The PASS predicted 
toxicity profile for Anguinomycin D and analog SB 640 are presented in Table 5.3. It can be observed 
from Table 5.3 that the toxicity profile whereby Pa>Pi for Anguinomycin D displays a higher 
probability of predicted toxicity in comparison to its counterpart SB 640. The range of toxicity varies, 
using an index whereby Pa>0.7 indicates that significant activity that can be observed experimentally; 
0.5<Pa<0.7 indicates that activity can be observed however minimal activity can be observed 
experimentally. Although this may be the case, the compound holds great biological significance as it 
may not be similar to current pharmaceutical agents. From the results projected in Table 5.3, it can be 
observed that the analog SB 640 displayed an overall reduction in the toxicity levels in comparison to 
the parent compound Anguinomycin D. Anguinomycin D displays increased predicted toxicity as an 
immunosuppressant, DNA and RNA synthesis inhibitor, which supersedes that predicted by the analog 
SB 640. The observed increase in toxicity levels displayed by Anguinomycin D may be attributed to 
the polyketide chain present in its   structure which is omitted in the analog SB 640. Although the 
polyketide chain is predominantly associated with a vast range of biological activity, recent studies have 
unveiled that its synthesis is affiliated with toxin production99. The presence of the polyketide chain is 
also found in Leptomycin B which is a close structural relative of the Anguinomycin family. 
Leptomycin B was found to be associated with dose-limiting toxicity and thus prompted its 
discontinuation as an inhibitor of CRM1 exportin protein14. 
 
Table 5.3. Toxicity Prediction of Anguinomycin D and SB 640.  
Activity                                                                                  Pa                   Pi   
Immunosuppressant                                                                0.801              0.005                                         
                                                                                                                                                0.745              0.012a 
DNA synthesis inhibitor                                                         0.672              0.007 
                                                                                                                                                0.402              0.028a 
RNA synthesis inhibitor                                                         0.642              0.002 
 
                                                                                                                                                0.488              0.008a 
HMG CoA synthase inhibitor                                                 0.574             0.001 
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                                                                                                                                                0.506              0.002a    
Protein synthesis inhibitor                                                      0.509              0.006 
                                                                                                0.500              0.006a 
ATPase inhibitor                                                                    0.496               0.002 
                                                                                                0.350              0.006a                  
Acylaminoacyl-peptidase inhibitor                                        0.443              0.023  
                                                                                                0.282              0.042a  
Lactase inhibitor                                                                     0.413              0.055 
                                                                                                0.294              0.146a  
Electron Transport Complex I inhibitor                                 0.047              0.022 
                                                                                                0.045              0.026a 
HIF1A expression inhibitor                                                    0.444              0.079  
                                                                                                0.348              0.135a                                                                                               
 
Pa: Coefficient of Activation   Pi: Coefficient of Inhibition   
a SB 640 
5.6. Conclusion   
Natural product analogs have timelessly displayed improved characteristics of solubility as well as 
pharmacokinetics and are thus constantly being targeted in drug design and synthesis. From the 
thermodynamics calculations projected in this study, it is observed that the derived analog SB 640 
exhibited slight reduction in binding affinity whilst still maintaining an overall retention of biological 
activity. Although being reduced by 60% in molecular weight, the analog SB 64 illustrated retention of 
biological activity in comparison with the parent compound Anguinomycin D, which is in 
correspondence with experimental studies conducted 14. The toxicity profile of SB 640 in comparison 
to the parent compound was substantially reduced, further highlighting that a reduction in the size of a 
compound may result in reduced toxicity. These fragments provide an ideal initial platform to assist 
medicinal chemists in drug design as they portray vital interactions thus reducing time constraints whilst 
and production costs. The use of structural analogs would aid in synthesis being much more time 
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efficient and thus bridging the gap of a lack of bioavailability of natural products. Further investigations 
into the “reduce to maximum” concept may be pivotal in expanding the horizon of the drug discovery.  
Supplementary Information  
RMSD of the C-alpha backbone of CRM1 in complex with Anguinomycin D and analog SB 640 
provided in the supplementary material. 
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CHAPTER 6 
6.0. General conclusion and future study recommendations  
 
6.1 General conclusions  
The major aims of this study were to validate the “reduce to maximum concept” utilising computational 
modeling approaches in a bid to contrive new alternative protocols that can be followed in next 
generation drug discovery. To generate a protocol that can be utilised to distinguish which fragments 
of a chemical compound must be retained for biological activity and which fragments can be omitted 
based on thermodynamic integrated calculations. In addition to providing significant molecular insight 
into the binding affinities and molecular mechanism interaction of the parent compound Anguinomycin 
D and derived analog SB 640. Estimating the toxicity profiles of parent compound Anguinomycin D in 
comparison to its structural analog SB 640. Another pivotal aim of this study was to highlight the use 
computational tools such as homology modeling in the drug design and discovery process.  Results 
from this work have led to the following conclusions:  
 
1. Although being reduced by more than 60 % in its structural composition, the derived analog of 
Anguinomycin D, SB 640 displayed only a minimal reduction in the binding affinity in 
comparison to the parent compound which corresponds with experimental studies conducted. 
The retention of biological activity exhibited by SB 640 may be attributed to the retention of 
the crucial α, β unsaturated ẟ-lactone moiety.  
2. The convergence of post-dynamic simulation of Anguinomycin D-CRM1 and analog SB 640-
CRM1 systems were validated by RMSF and Rg potential energy plots. The RMSF of both the 
parent compound and analog SB 640 in complex with the NES binding groove of the CRM1 
protein displayed a relatively rigid and stable systems. With the parent compound 
Anguinomycin D-CRM1 complex displaying a greater amino acid fluctuation in comparison to 
the analog SB 640. 
3. From the Rg potential energy plot, the analog SB-640-CRM1 complex displayed an overall 
stable system as compared to Anguinomycin D-CRM1 system which exhibited prominent 
flexibility. The high level of stability exhibited by the analog SB 640 can be attributed to its 
compact size and ability to position itself deeper, as displayed by Figure 5.7 within the active 
site. 
4. From the thermodynamics calculations performed it can observed, that the electrostatic 
interaction exhibited by the analog SB 640 supersedes that of the parent compound, the 
observed increased in the electrostatic interactions can be correlated to the conformational pose 
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undertaken by the analog SB 640 within the hydrophobic NES binding groove of the CRM1 
protein. However the parent compound Anguinomycin D displayed a higher van der Waal 
contribution to the binding of the NES binding groove of the CRM1, which can be attributed 
to the presence of the polyketide chain which is omitted in the structure of the analog SB 640.   
5. Per-residue energy decomposition analysis displayed energetically favourable contributions 
from amino acids Leu 536, Thr 575, Val 576 and Lys 579, these prominent amino acid residues 
were conserved in the analog SB 640-CRM1 and Anguinomycin D-CRM1 complexes. 
Elucidating which fragments of a chemical compounds is essential for retention or enhanced 
biological activity and which fragments can be omitted.   
6. Toxicity profiling of the parent compound Anguinomycin D displayed a greater level of toxicity 
of the parent compound in comparison to the analog SB 640, which can be allocated to the 
presence of the polyketide chain present in the parent compound. Highlighting that the 
reduction in the size of a compound may result in reduced toxicity exhibited by the analog SB 
640.  
7. The reduce to maximum concept demonstrates the potent activity of compact structural 
analogues, which was further validated in this study, the execution of this concept may enable 
better synthetic approachability of chemical fragments derived from natural products.   
8. Homology modeling was identified as a prominent tools in drug discovery, identifying its 
various applications as well as providing a conclusive protocol that can be followed to generate 
the most accurate yet optimal 3D protein structure.  
 
6.2 Future study recommendations  
Strategic computational techniques presented in this work will serve as beneficial tools to enhance novel 
drug discovery and development process. This study displays the potential use for the “reduce to 
maximum concept “to be implemented in all spheres of drug design and discovery. As the data extracted 
from this study displays the retention of biological activity, reduced toxicity and enhanced synthetic 
approachability of the derived analog although being reduced by more than 60% in its structural 
composition form that of the parent compound Anguinomycin D. This study displays the use of 
computational approaches such as thermodynamic calculations that can be utilised to isolate and 
reproduce only the most essential chemical fragments derived from natural products that can be used in 
drug discovery. As well as highlights which fragments can omitted as their presence may result in the 
toxic effect displayed by many pharmacological drugs and so the implementation of this study may 
prevent the synthesis of unwanted and toxic component of chemical fragments, this study in 
combination with chemical synthesis and prospective biological testing of lead compounds identified 
may alleviate the pending crisis of lack of new prospective drug candidates required for rational drug. 
The implementation of homology modeling in drug design and discovery protocols to generate the most 
accurate model, increasing the specificity of potential drug candidates ultimately leading to the effective 
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treatment of disease conditions. Further validation of the data extracted from this study may provide 
insight into the direct molecular interactions with regard to the distribution of motion, providing further 
into the exact binding mode adopted by the analog in comparison to the parent compound. This can be 
accomplished by performing Principal Component Analysis (PCA), Residue Interaction Network 
(RIN), and Substrate Envelope Analysis (SEA). Application of these methods may provide vital insight, 
elaborating the enzyme dynamics, drug-enzyme interactions and conformational structural changes. 
 
      
APPENDIX  
111 
 
APPENDIX  
 
 
 
A1. RMSD of the C-alpha backbone of CRM1 in complex with Anguinomycin D (black) and 
analog SB 640 (red).
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